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Abstract 
Osteoarthritis (OA) is a multifactorial joint disease and one of the leading causes of 
pain and disability in older adults. It has long been hypothesised that synovium plays an 
important role in the initiation and progression of OA. This thesis aims to investigate the 
associations between synovial inflammation in the knee and important disease outcomes of 
OA, and the therapeutic effects of vitamin D supplementation on synovial inflammation. 
 This thesis utilises data from two clinical studies. The first one is a cohort study with 
a total number of 977 participants randomly selected from the local community (51% female; 
aged 62 ± 7 years) at baseline. 404 participants were followed up approximately 2.7 ± 0.4 
years later.  Synovial inflammation (assessed as effusion-synovitis), cartilage volume, 
cartilage defects, tibial bone area, and bone marrow lesions (BMLs) were assessed using 
magnetic resonance imaging (MRI). X-ray was used to assess radiographic changes including 
joint space narrowing (JSN) and osteophytes. Questionnaires were used to assess knee pain, 
knee function, knee stiffness, physical activity, and other disease status.  
Another study is a multi-centre, parallel, randomised, placebo-controlled trial which 
was conducted in symptomatic knee OA patients aged 63 ± 7 years (208 females). 413 
patients were allocated to either a 50,000 IU monthly vitamin D3 capsule (n=209) or placebo 
(n=204) for 24 months. Knee effusion-synovitis, cartilage defects, cartilage volume and 
BMLs were assessed using MRI. Knee symptoms were assessed at baseline and months 3, 6, 
12, 24 using Western Ontario and McMaster University Index of OA (WOMAC) 
questionnaire. Serum 25-hydroxylvitamin D (25-(OH)D) was assayed by Liaison method 
utilising a direct competitive chemiluminescent immunoassay. 
In Chapter 4 the cross-sectional and longitudinal associations between site-specific 
effusion-synovitis and knee pain were examined in older adults. We found that effusion-
synovitis in the suprapatellar pouch was consistently associated with weight-bearing and non-
weight-bearing pain while those in central and posterior sites were only associated with non-
weight-bearing (inflammatory) knee pain. These associations were independent of age, sex, 
body mass index (BMI), cartilage defects, BMLs and ROA. 
In Chapter 5, we examined if effusion-synovitis was associated with knee structural 
changes cross-sectionally and longitudinally in older adults. Suprapatellar pouch effusion-
synovitis at baseline predicted the development/progression of cartilage defects and BMLs as 
well as cartilage volume loss. Effusion-synovitis was independently associated with cartilage 
defects after adjustments for other structural abnormalities. The associations between 
Abstract   
 
 X 
effusion-synovitis and BMLs and cartilage volume were largely dependent on cartilage 
defects, suggesting potential causal pathways. 
In Chapter 6, natural history and clinical significance of quantitatively measured 
effusion-synovitis were described in older adults. The mean (±SD) size of effusion-synovitis 
in participants was 1.64 cm2 (±1.34 cm2) at baseline with 29% improving and 22% worsening 
in size over 2.7 years. Males had larger effusion-synovitis size than females. Baseline 
effusion-synovitis also positively associated with changes in cartilage defects and BMLs, 
while it is negatively associated with change in cartilage volume. No associations were found 
between baseline structural alterations and change in effusion-synovitis size.  
In Chapter 7, we further examined clinical relevance of effusion-synovitis using 
effusion-synovitis volume measurement in patients with knee OA. Baseline BML, cartilage 
defect, JSN and osteophyte scores were significantly associated with the change in effusion-
synovitis volume. However, neither baseline effusion-synovitis volume nor score was 
significantly associated with changes in BMLs, cartilage defects or cartilage volume. There 
were no significant associations between knee effusion-synovitis volume and measures at 
patellofemoral joint. 
In Chapter 8, the effects of vitamin D supplementation on effusion-synovitis were 
determined in patients with knee OA. Baseline effusion-synovitis volume was 8.0 ml with a 
prevalence of 52%. After a 24-month intervention, the vitamin D group had a less increase in 
total effusion-synovitis volume than the control group (between group difference: -1.94 ml, p 
=0.02). The between-group differences were particularly significant in suprapatellar pouch 
region, and in patients who had effusion-synovitis at baseline. 
In conclusion, the series of relevant studies indicate that synovial inflammation plays 
a pivotal role in the pathogenesis of knee OA. Synovial inflammation contributed to knee 
pain and predicted the development or progression of disease outcomes such as cartilage 
defects and BMLs in older adults, most of them being in early stages of osteoarthritic 
changes; in contrast, cartilage defects and bone abnormalities accelerated progression of 
effusion-synovitis only in those with established OA. Vitamin D as an attractive therapeutic 
intervention has shown a beneficial effect on halting the worsening of effusion-synovitis in 
knee OA patients. Our work suggests that effusion-synovitis can be used as a disease 
diagnostic feature and an outcome measure in OA trials. Targeting on the effusion-synovitis 
can be implicated for future development of disease-modifying OA drugs (DMOADs). Future 
work is required to confirm the relationship between effusion-synovitis and joint structural 
changes in patients with early and/or late stages of OA in longer-term cohort studies. Clinical 
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trials are also needed to examine whether treatments such as vitamin D supplementation can 
reduce progression of effusion-synovitis (as the primary outcome) in knee OA patients with 
inflammatory phenotype. 
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Synopsis 
OA is the most common form of arthritis and a leading cause of musculoskeletal pain 
and disability. Although its signature pathologic feature is articular cartilage loss, many other 
joint structures, including subchondral bone, ligaments, menisci, periarticular muscles, 
peripheral nerves, and synovium were also involved. It was hypothesised that synovial 
inflammation plays an important role in disease pathogenesis of early OA. There is emerging 
evidence to support this; however, it remains controversial whether synovial inflammation 
precedes cartilage damage. This thesis examines the role of effusion-synovitis in preclinical 
and clinical OA using data from a prospective population-based study in community-
dwelling older adults and a clinical trial in patients with knee symptomatic OA. Specifically, 
it compares quantitative and semi-quantitative effusion-synovitis measures in different joint 
subregions and explores how these measures relate to disease severity and progression. This 
synopsis presents an overview of the content of each chapter. It further investigates the 
effects of vitamin D supplementation on effusion-synovitis in knee symptomatic OA patients 
using data from a RCT. 
 
Chapter 1 provides an overview of knee OA with a focus on the synovial membrane. A 
working definition is provided and the economic impact, burden of disease, symptoms, risk 
factors, treatment and management options are discussed. A description of the radiographic 
and clinical criteria for the diagnosis of knee OA is presented. Notably, this chapter presents 
an overview of the physiological and pathological roles of joint fluid and how it relates to 
clinical outcomes in OA. It then provides an outline of different MRI assessment systems in 
measuring synovial abnormalities. Lastly, this chapter summed current treatments that 
targeted on synovial inflammation in OA research. 
 
Chapter 2 lists the research questions to be addressed in the thesis. 
 
Chapter 3 describes two studies, the Tasmanian Older Adult Cohort (TASOAC) and the 
Vitamin D Effect on Osteoarthritis study (VIDEO), which are used in this thesis, 
respectively. It describes the study population and its design, as well as the protocols for 
measurement of factors, which are common to multiple chapters in this thesis. Additional 
factors, which are unique to each chapter, are described in more detail in the methodology 
section of the subsequent chapters.  
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Chapter 4 describes the cross-sectional and longitudinal associations between knee regional 
effusion-synovitis and knee pain in older adults.  Data from a population-based random 
sample (N = 880, mean age 62 years; 50% females) was used. Baseline knee joint effusion-
synovitis was graded (0-3) using T2-weighted MRI in suprapatellar pouch, central portion, 
posterior femoral recess, and subpopliteal recess. Effusion-synovitis of the whole joint was 
defined as a score of 2 in any subregion. Other knee structural (including cartilage, bone 
marrow and menisci) lesions were assessed by MRI at baseline. Knee pain was assessed by 
WOMAC questionnaire at baseline and 2.6 years later. Multivariable analyses were 
performed after adjustment for age, gender, BMI and other structural lesions. The prevalence 
of effusion-synovitis was 67%. Suprapatellar pouch effusion-synovitis was significantly and 
independently associated with increased total and non-weight-bearing knee pain in both 
cross-sectional and longitudinal (for an increase in total knee pain of 5: RR, 1.26 per grade, 
95% CI: 1.04, 1.52) analyses, and increased weight-bearing knee pain in the longitudinal 
analysis only. Effusion-synovitis in posterior femoral recess and central portion were 
independently associated with increases in non-weight-bearing pain (RR: 1.63 per grade, 
95% CI: 1.32, 2.01; RR: 1.29 per grade, 95% CI: 1.01, 1.65, respectively) in longitudinal 
analyses only. In conclusion, knee joint effusion-synovitis has independent associations with 
knee pain in older adults. Suprapatellar pouch effusion-synovitis is associated with non-
weight-bearing and weight-bearing knee pain, while posterior femoral recess and central 
portion effusion-synovitis are only associated with non-weight-bearing pain. 
  
Chapter 5 describes the cross-sectional and longitudinal associations between knee regional 
effusion-synovitis and structural changes in older adults. A total of 977 subjects were 
randomly selected from the local community (mean 62 years, 50% female) at baseline and 
404 were followed up 2.6 years later. T2-weighted MRI was used to assess knee effusion-
synovitis in four subregions: suprapatellar pouch, central portion, posterior femoral recess 
and subpopliteal recess. Knee cartilage defects, cartilage volume and bone marrow lesions 
(BMLs) were measured using MRI at baseline and follow-up. Cross-sectionally, effusion-
synovitis in most subregions was significantly associated with higher risks of cartilage 
defects, BMLs and reduced cartilage volume. Longitudinally, suprapatellar pouch effusion-
synovitis at baseline predicted an increase in cartilage defects (p<0.01), loss of cartilage 
volume (p=0.04) and an increase in BMLs (p=0.02) in multivariable analyses. The significant 
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associations of effusion-synovitis with cartilage volume and BMLs disappeared after 
adjustment for cartilage defects. Effusion-synovitis in the whole knee joint (p<0.01) and 
subpopliteal recess (p<0.05) was consistently associated with longitudinal changes in 
cartilage defects but not in cartilage volume and BMLs. To sum up, there are independent 
associations between knee joint effusion-synovitis and knee cartilage defects in both cross-
sectional and longitudinal analyses, suggesting a potential causal relationship. The 
associations of effusion-synovitis with BMLs and cartilage volume were largely dependent 
on cartilage defects, suggesting potential causal pathways. 
 
Chapter 6 describes the natural history of quantitatively measured knee effusion-synovitis 
and the longitudinal associations between effusion-synovitis and knee structural factors 
including cartilage defects, cartilage volume, subchondral BMLs and meniscal pathology in 
older adults. A total of 406 subjects were randomly selected (mean 62 years, 50% females) at 
baseline and followed up 2.7 years later. T2 or T1-weighted fat saturation MRI was used to 
assess the knee effusion-synovitis maximal area, cartilage defects, cartilage volume, BMLs 
and meniscal pathology at baseline and follow-up. Multivariable generalized linear 
regressions were performed to analyse the associations between the maximal area of effusion-
synovitis and other joint structural factors after adjustment for age, gender, BMI, tibial bone 
area and/or radiographic OA (ROA). Over 2.7 years of follow-up, the size of effusion-
synovitis increased in 29%, remained stable in 50% and decreased in 22% of the participants. 
Baseline effusion-synovitis maximal area was significantly associated with changes in knee 
cartilage defects (β: 0.18, 95% CI: 0.07, 0.29), BMLs (β: 0.17, 95% CI: 0.05, 0.30), and 
cartilage volume (β: -0.40, 95% CI: -0.71, -0.09) but not with change in meniscal pathology. 
In contrast, baseline structural measures were not associated with change or increase in 
effusion-synovitis maximal area. Knee effusion-synovitis was not static in older adults. It was 
predictive of, but not predicted by, other structural abnormalities suggesting a potential role 
in knee early osteoarthritic changes. 
 
Chapter 7 investigates the associations between effusion-synovitis and joint structural 
abnormalities in patients with knee OA over 24 months. A total of 413 symptomatic OA 
patients (age 63.2 ± 7.0 years, 208 females) were recruited. Knee pain, function and stiffness 
were assessed by WOMAC. Knee effusion-synovitis volume and score (0-3), cartilage defects, 
cartilage volume and BMLs were assessed using T1/T2-weighted MRI. Baseline JSN and 
osteophytes were assessed. Multivariable linear regression or multilevel generalised mixed-
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effects linear or ordinal logistic regression models were used to analyse the longitudinal 
associations. Total effusion-synovitis volume increased significantly from baseline (8.0 ± 8.5 
ml) to follow-up (9.0 ± 10.5 ml). Change in effusion-synovitis volume was positively 
correlated with changes in knee pain, function and stiffness scores (all p <0.05). In the 
generalised mixed-effects models, knee effusion-synovitis was positively associated with total 
BMLs (volume: β=1.16; score: OR=1.74, both p<0.001) and total cartilage defects (volume: 
β=2.25; score: OR=2.26, both p<0.001) scores, and negatively associated with total cartilage 
volume. Baseline total BML, cartilage defect, JSN and osteophyte scores were positively 
associated with change in effusion-synovitis volume (all p<0.05). Baseline cartilage defects 
and JSN were also associated with change in effusion-synovitis score (all p<0.05). However, 
neither baseline effusion-synovitis volume nor score was significantly associated with change 
in above structures. Knee joint effusion-synovitis was associated with symptoms, and was 
predicted by cartilage and subchondral bone abnormalities. These suggest that synovial 
inflammation is clinically relevant and can be the result of joint structural abnormalities in 
patients with established knee OA. 
 
Chapter 8 examines the effect of vitamin D supplementation on synovial inflammation in 
patients with knee OA and low vitamin D levels over 24 months. Symptomatic knee OA 
patients with a low 25-(OH)D level (12.5 to 60 nmol/l) were recruited for a multi-centre, 
randomised, placebo-controlled and double-blind trial. 413 patients (age 63.2±7.0 years, 208 
females) were allocated to either 50,000IU monthly vitamin D3 orally (n=209) or placebo 
(n=204) for 24 months. Changes in knee effusion-synovitis volume and score (0-3) were 
assessed using MRI. The least significant change criterion (LSC) was used to define as an 
increase or a decrease in effusion-synovitis volume. At baseline, mean total effusion-
synovitis volume was 8.0 ml with a prevalence of 48% (score  2). Over 24 months, total 
effusion-synovitis volume remained stable in the vitamin D group (mean change: 0.26 ml) 
but increased significantly in the placebo group (mean change: 2.20 ml). There was a 
significant difference between groups (-1.94 ml, 95% CI: -3.54, -0.33). This effect was 
evident in those with baseline effusion-synovitis (difference: -2.04 ml, 95%CI: -3.83, -0.25) 
and in the suprapatellar pouch (difference: -2.49 ml, 95%CI: -4.74, -0.25). The proportions 
with increases in total (relative risk: 0.66, 95%CI: 0.49, 0.90) and suprapatellar (relative risk: 
0.64, 95%CI: 0.44, 0.93) effusion-synovitis volume were lower while the proportion with the 
decrease in suprapatellar pouch effusion-synovitis was higher in the vitamin D group than in 
Synopsis   
 
 5 
the placebo group. This secondary analysis suggested that vitamin D supplementation can 
retard the progression of effusion-synovitis in patients with knee OA and low 25-(OH)D 
levels. Effusion-synovitis volume is clinically related to osteoarthritic changes and it has a 
modifiable nature suggesting it can be utilised as a sensitive outcome measure in OA trials. 
 
Chapter 9 summarises the findings of the thesis and also provides a number of potential 
directions for future research based on these findings.
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1.1 Overview of osteoarthritis 
 Osteoarthritis (OA) is the most common musculoskeletal disorder, affecting 
approximately 1.8 million Australians (8% of the population) (1). It is one of the leading 
causes of impaired mobility among older adults, characterised by pain and declining physical 
function (2), and eventually, in some cases, will lead to joint replacement surgery. A number 
of risk factors, including age, female sex, obesity, injury, quadriceps weakness and 
malalignment, contribute to both the onset and progression of OA (3). 
 Primary OA is an idiopathic disease afflicting a few or many joints, which is known as, 
generalised OA. Secondary OA is attributable to a cause, such as injury, congenital or 
developmental disorders of joints, but might have similar disease processes as primary OA 
(4). Our recent narrative review suggests that metabolic dysfunction or low-grade 
inflammation contributes to form a potential OA phenotype (Appendix 1), sharing similar 
aetiology as obesity and diabetes (5). 
 As a multifactorial disease, it is increasingly recognised that OA affects all structures 
within a joint, with multiple causal pathways being involved in its aetiology (6). Figure 1.1 
shows the articular cartilage loss, bone remodelling as well as abnormalities related to peri-
articular structures including muscles, meniscus, ligaments, synovium and subchondral bone 
marrow. Cartilage and subchondral bone are susceptible to abnormal external mechanical 
stress and internal biochemical and morphological changes, thus lose the function of 
absorbing biomechanical forces. Similarly, muscles, ligaments and menisci can fail due to 
injury or weakness, causing a breakdown in biomechanical function and amplification of 
physical stresses. The synovium in OA can exhibit inflammatory responses, which further 
damage surrounding tissues through the release of pro-inflammatory mediators into the 
synovial fluid (7). This interdependence among tissues underpins the multifactorial nature of 
the disease, with the loss of normal function in one tissue directly influencing another. Thus, 
OA rarely has a single cause and often presents a variety of pathological features and 
symptoms. 
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Figure 1.1. Articular structures that are affected in OA (8). 
 
 The development and progression of OA can be classified into four stages (9). The 
changes to the healthy joint in the first stage often involve abnormal growth of the 
subchondral bone and disruption to cartilage homeostasis, reflected by increased bone and 
cartilage biomarkers in the blood. This is followed by a preclinical stage involving structural 
changes in the cartilage and surrounding tissues which are now detectable by magnetic 
resonance imaging (MRI). The third stage is represented by definite cartilage loss and bone 
remodelling including outgrowths known as osteophytes, both of which are visible on 
radiographs. The cartilage fragments and breakdown products build up in the synovial fluid, 
interfering with the mechanical operation of the joint and stimulating a pro-inflammatory 
response from the synovium and adjacent tissues. The fourth or end-stage is total joint 
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dysfunction, which is characterised by catastrophic damage to the articulating surfaces and a 
loss of joint function, which can only rely on joint replacement. Systemic metabolic and 
inflammatory factors predominate in the early stages of OA, whereas mechanical factors 
seem to be more important in the later stages (9). 
 
1.1.1 Disease prevalence and burden 
Approximately 10-12% of the adult population have symptomatic OA. The risk of 
disability attributable to knee OA alone is greater than that attributable to any other medical 
condition in people aged over 65 years (10). Estimates published in 2012 suggest that 250 
million people worldwide are affected by knee OA (1). On the basis of international 
radiological survey data, the Australian Institute of Health and Welfare (AIHW) estimated 
that there are more than 40,000 new cases of radiological OA each year, adding to the large 
pool of prevalent OA, which will continue to grow as our population ages (11). Prevalence of 
symptomatic OA increases to 10% of men and 20% of women aged 45–65 years. 
Radiological prevalence surveys suggest much higher rates than this, with changes of OA 
being present on X-ray in more than 50% of people aged over 65 years (10). 
Based on AIHW disease expenditure data, $1.6 billion was attributed to OA in 2008-
09 (the most recent year for which data are available). This expenditure consisted of: $1,256 
million on admitted patient costs (76.7%); $282 million on out-of-hospital-costs (17.2%); $99 
million on prescription pharmaceuticals (6.0%) (1). Furthermore, the expenditure on OA may 
not be fully captured due to lack of comprehensive information, such as on allied health costs 
and over-the-counter medications. In 2012-13, 40,255 total knee and 25,169 hip replacement 
procedures were performed (1). The symptoms and disability of patients will lead to loss of 
wellbeing and health which further contributes to the costs of OA. It is critical that both the 
current economic climate and rapidly increasing burden from OA call for urgent attention to 
this matter. 
 
1.1.2 Clinical symptoms 
The most common symptom in OA is joint pain. Patients also experience stiffness, 
swelling, tenderness, inflammation, crepitus, instability, loss of motion, and muscle 
weakness. These symptoms lead to a limitation of mobility, physical and psychological 
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disability and impaired quality of life. Patients often experience major difficulties in daily 
activities including walking, running and stair-climbing (12). 
 
1.1.3 Risk factors 
OA used to be regarded as a degenerative joint disease resulting from “wear and tear” 
and the inevitable effects of aging (13). Women are more likely to have knee and hand OA 
than men and also have more severe OA (14). Other systemic risk factors include 
race/ethnicity, genetics, congenital or developmental condition (15).  
One of the most well-agreed risks in OA is obesity, especially for weight-bearing 
joints. Outside the mechanical loading, being overweight can also lead to OA through 
increasing the metabolic and inflammatory effects (16). Past joint injury is a consistent risk 
factor that can result in damage to cartilage as well as other tissues (17). Trans-articular 
fracture, meniscal tear requiring meniscectomy or anterior cruciate ligament (ACL) injury 
can result in increased risks of knee OA and musculoskeletal symptoms (18). Additional risk 
factors include occupational activity, and mechanical factors such as physical activity, 
adduction moment, malalignment and muscle weakness (19, 20).  
 
1.1.4 Treatment and management  
Most guidelines have recommended various options including non-pharmacological, 
pharmacological and surgical therapies for OA treatment. Since there were no effective 
disease-modifying osteoarthritis drugs (DMOADs) approved for OA structural improvement, 
current therapies are mostly palliative and are concerned with controlling pain and improving 
function. Acetaminophen, oral and topical non-steroidal anti-inflammatory drugs (NSAIDs), 
tramadol and opioids have variably been recommended for symptom relief and control joint 
inflammation (21). According to a population-based study, the drugs most frequently used for 
OA therapy are chondroitin (21.2%), glucosamine (15.8%) and oral NSAIDs (14.4%), and 
the incidence of the use of opioids, cyclooxygenase-2 (COX-2) inhibitors and chondroitin 
increased over 5-year period, whereas all others decreased (22). Injections of hyaluronic acid 
(HA) into the knee joint have been approved by the Food and Drug Administration (FDA) for 
the treatment of OA, but data on efficacy are inconsistent. Recent meta-analyses reported 
statistically significant but limited efficacy (23). Glucosamine and chondroitin sulphate are 
widely used for the treatment of OA, although their mechanisms of action are unclear. Most 
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RCTs have reported moderate effects in reducing OA symptoms with either compound but 
larger than with placebo with little toxicity (24). 
According to most current guidelines, the mainstay of treatment and what represents 
the call for everyone with OA should consist of non-pharmacologic approaches first, 
typically including weight loss, lifestyle modification, physiotherapy, and exercise (25-27). 
There is strong evidence to show that exercise has beneficial effects on pain and function, and 
a combination of strengthening, aerobic and functional exercise is recommended (28). 
Exercise helps to lose weight, strengthen muscles, increase the range of motion, improve 
proprioception, balance, cardiovascular fitness, and relief emotional stress (29, 30). 
Importantly, exercise has similar effects to analgesic and anti-inflammatory medications, but 
has fewer contraindications and adverse events than drugs and surgery (29, 31). However, 
exercise might not dramatically modify disease progression, additional physiotherapies are 
recommended in assisting with OA interventions include taping, bracing, wedged insoles, and 
manual therapy (32-34). 
If conservative therapy fails, surgery therapies should be considered, which included 
arthroscopy, cartilage repair, osteotomy, and knee arthroplasty. Determining which of these 
procedures is most suitable depends on location, stage of OA and comorbidities etc. 
Arthroscopic lavage is often carried out, but does not change disease progression. If OA is 
limited to one compartment, uni-compartmental knee arthroplasty or unloading osteotomy 
can be considered (35). Ultimately, when other treatment has failed and OA advanced 
greatly, knee arthroplasty is performed. Due to its irreversible nature, though, only applied in 
the most severe cases (36). 
 
1.2 Knee OA diagnostic criteria 
The knee joint is the weight-bearing site that is often affected by pain, which is 
typically attributed to OA and, a leading cause of chronic disability in older persons (37-39). 
This thesis will focus on knee OA. 
 
1.2.1 Radiography 
 Conventional X-ray remains the main test for the diagnosis of knee OA. Most of the 
developed radiological scoring systems include the assessment of osteophytes, joint space 
narrowing (JSN) and width, subchondral sclerosis, and bony attrition. The most commonly 
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used method is the Kellgren and Lawrence (K-L) grading system (40). The cut-off point of 
two or more comprises the radiological definition of OA in clinical studies as shown in 
Figure 1.2. 
 
 
Figure 1.2. Kellgren Lawrence (K-L) grading scale on radiographic knee OA (40). 
 
More recently developed scales, such as the Osteoarthritis Society International 
(OARSI) radiographic atlas (41), define each discernible radiographic characteristic of OA 
including osteophyte and JSN, in the hand, hip and knee. This system has the advantage of 
scoring each radiographic feature separately, whereas a composite measure such as the K-L 
grade may hinder the understanding of each separate radiographic component of OA. 
 
1.2.2 Clinical criteria 
Diagnostic criteria for OA have been developed by the American College of 
Rheumatology (4). These criteria include a combination of the patient’s age, signs and 
symptoms on physical exam, radiographic and/or laboratory evidence. When the radiograph 
is used along with physical exam, the sensitivity and specificity of this method are 91% and 
86%, respectively (Table 1.1). More recently, The European League Against Rheumatism 
(EULAR) OA Task Force suggests that a confident clinical diagnosis of knee OA may be 
made according to three symptoms (persistent knee pain, morning stiffness and reduced 
function) and three signs (crepitus, restricted movement and bony enlargement) (42).
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Table 1.1. Criteria for diagnosis of knee osteoarthritis (43). 
Clinical criteria 
 
- Age older than 50 years 
- Activity-related joint pain 
 - Bony enlargement 
 - Bony tenderness 
 - Crepitus 
 - No palpable warmth 
 - Stiffness for < 30 minutes 
Laboratory criteria 
 - Erythrocyte sedimentation rate < 40 mm/hour 
 - Rheumatoid factor < 1:40 
 - Synovial fluid analysis: clear, viscous, white blood cell count < 2,000/µL (2.00×109 per L) 
Radiographic criteria 
 - Presence of osteophytes     
  Sensitivity (%) Specificity (%) LR+ LR– 
 - Pain plus ≥ 3 clinical criteria 95 69 3.1 0.07 
 - Pain plus ≥ 5 clinical or laboratory criteria 92 75 3.7 0.11 
  
- Pain plus ≥ 5 clinical or laboratory criteria, 
plus osteophyte 91 86 6.5 0.1 
LR+ = positive likelihood ratio; LR– = negative likelihood ratio.    
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1.2.3 Magnetic resonance imaging 
The diagnosis of OA by radiographs used to be a “gold standard” to define and 
monitor disease progression in many epidemiological and clinical studies. However, the 
continued use of plain radiography has many limitations. Many studies have shown that 
radiographic features such as JSN and osteophytes do not correlate well with clinical 
symptoms (44, 45). It has been reported that less than 50% of people with evidence of OA on 
X-rays have symptoms related to these findings (46). Radiographs are also insensitive to 
early disease alterations and require longer study duration to detect significant changes. By 
the time that radiographic changes are detected, 10% of knee cartilage has already been lost 
(47). JSN is influenced by many joint structures including cartilage and meniscus, which 
cannot be separated by radiographs. 
Magnetic resonance imaging (MRI) has proven to be an important tool in OA 
research and has revolutionised the understanding of OA pathology. MRI can visualise all 
tissues in the joint involved in OA including cartilage, menisci, bone marrow, and soft 
tissues. While costly, MRI is free of ionising radiation and has good tissue contrast and 
anatomical resolution allowing for the non-invasive examination of joint structures. MRI is a 
useful tool to study early stages or even pre-OA. There is increasing evidence to demonstrate 
that structural changes can be measured both reliably and with good responsiveness on MRI 
(48). Numerous studies have examined the use of MRI in effusion-synovitis, meniscus 
pathology, cartilage morphology alteration, bone marrow lesions (BMLs), osteophytes, 
cartilage composition, and other markers along with their correlations with clinically defined 
OA (49). Despite the growing pool of information, there is little uniformity in the diagnostic 
application of MRI and a lack of its confirmed diagnostic utility, as noted in the “Evidence 
Based Recommendations for the Diagnosis of Knee OA” published by EULAR in 2009 (42).  
The OARSI Food and Drug Administration (FDA) OA initiative has developed a MRI 
definition of knee OA which has been used in several recent studies (50), it suggests that 
further testing should focus on comparisons other than the radiograph, that may capture later 
stage disease and thus nullify the potential for detecting early disease that MRI may afford.  
 
1.3 Synovium in OA 
An important emerging theme in OA is broadening the focus of the disease from 
cartilage only to the whole joint. The cartilage, bone and soft tissues are each involved in 
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pathological processes that lead to progressive joint degradation. The synovial abnormalities 
have been observed at multiple stages of OA, suggesting it plays an important role in OA 
pathogenesis supported by increasing evidence (51, 52). This thesis investigates the role that 
synovium membrane plays in OA using data from a prospective population-based study of 
older adults and a RCT of knee OA patients. It focuses on MRI-detected synovial measures, 
included synovial fluids (effusion) and synovitis in different locations of a knee joint, and 
investigated how it is related to disease severity and progression. A detailed introduction 
specific to each research question will be presented at the start of Chapters 4 to 8. This 
section presents an overview of how synovial membrane involved in healthy and 
osteoarthritic joint and describes the clinical impact of synovial inflammation on OA-related 
symptoms and structural changes. 
 
1.3.1 Physiology and function 
The articular capsule surrounding synovial joint consists of a thick outer layer, the 
fibrous capsule and a more delicate inner layer, the synovial membrane. The highly vascular 
synovial membrane lines the non-articular portions of the synovial joint as well as the intra-
articular ligaments and tendons (53). The normal synovium provides a deformable packing 
that allows movement of adjacent non-deformable tissues (54). Composed of thin connective 
tissue, it includes the continuous surface layer of cells (intima) and the underlying tissue 
(subintima). The intima consists of macrophages and fibroblasts while the subintima includes 
blood, lymphatic vessels and nerve fibres. The microscopic anatomy of normal synovial 
tissue often falls into three main types based on the content of the subintima layer: fibrous, 
areolar and adipose. Areolar synovium may also have specialized viscoelastic properties for 
coping with stretching, rolling and folding it undergoes during joint movement (54). (Figure 
1.3). Furthermore, the cellular elements of the synovium were responsible for the secretion of 
the viscid synovial fluid, which lubricates and nourishes the joint. Synovial fluid is an 
ultrafiltrate or dialysate of plasma, which contains hyaluronan (hyaluronic acid), lubricin 
(also known as proteoglycan-4), surface-active phospholipids (SAPL), proteinases and 
collagenases (55). The synovial fluids also have a role in the removal of metabolic wastes 
(e.g. carbon dioxide and products of matrix turnover) and intra-articular particulate matter 
(i.e. cartilaginous debris), which could be diffused in the fluid or deposited within the 
membrane (54, 56). 
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Figure 1.3. The schema of the synovial membrane (57). 
 
Joint effusion may result from mechanical irritation by worn cartilage and bone, with 
the normal composition of the synovial fluid and excessive production of hyaluronan by 
intimal fibroblasts stimulated by frictional forces, such as in OA. On the other hand, joint 
effusion in an inflammatory synovitis is likely to be an accumulation of exudate similar to a 
pleural effusion, for example, an overspill from the inflammatory edema in synovial tissue 
created by increased vascular permeability (54). However, recent evidence suggests that low-
grade inflammatory and immune reaction also contribute to the pathogenesis of OA, 
implicating that these two mechanisms of effusion development may not be as distinct as 
originally thought (58). 
 
1.3.2 Synovial anatomy of the knee joint 
The synovial membrane of the knee joint attaches to the margins of the articular 
surfaces and to the superior and inferior outer margins of the menisci. It lines the joint 
capsule except posteriorly where cruciate ligaments were found (Figure 1.4A). The two 
cruciate ligaments, which attach in the inter-condylar region of the tibia below and the inter-
condylar fossa of the femur above, are outside the articular cavity, but enclosed within the 
fibrous membrane of the knee joint. Posteriorly, the synovial membrane reflects off the 
fibrous membrane of the joint capsule on either side of the posterior cruciate ligament (PCL) 
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and loops forward around both ligaments thereby excluding them from the articular cavity. 
Anteriorly, the synovial membrane is separated from the patellar ligament by an infrapatellar 
fat pad (53) (Figure 1.4B). 
 
 
Figure 1.4. The synovial anatomy of a knee joint (59).  
(A) Superolateral view of the synovial membrane (showed in red). (B) Paramedial sagittal 
section through the knee. 
Understanding of the synovial anatomy allow not only to illustrate a variety of 
structural changes involving them, but also to make the investigations possible regarding the 
location-specific pathology of a joint. Figure 1.5 demonstrates the synovial lining of the knee 
joint which forms several interconnected compartments. First, in the central portion of the 
joint, the synovial fluid can be observed between the patella and femoral shaft (yellow 
arrow), extending medially and laterally deep to the patellar retinacula (Figure 1.5A). The 
fluid can also accumulate (yellow arrow) in the deep part of the central recess, around the 
ACL and PCL (Figure 1.5B-C). Second, the synovial fluid can be detected in the 
suprapatellar pouch which extending superiorly from the upper surface of the patella (yellow 
arrow). This large pouch is formed between the quadriceps tendon anteriorly and femur 
posteriorly (Figure 1.5D-E). Third, the synovial membrane extends posteriorly from lateral 
and medial sides of the femur (yellow arrow) and forms recesses above the posterior portions 
of both condyles (Figure 1.5F-G). In the midline, the posterior capsular recess may become 
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an extension from the medial tibiofemoral compartment that behind the PCL (Figure 1.5B). 
Sub-popliteal recess as a small pouch can be seen between the lateral meniscus posteriorly 
and the popliteus tendon. Occasionally, the lining is continuous with the synovial membrane 
of the proximal tibiofibular joint. There is also a recess that frequently observed during 
arthrography superior to the posterior third of the medial meniscus (53). Anatomic variation 
of synovitis has been reported and it was most commonly observed posterior to the PCL and 
in the supra-patellar (60), but whether synovitis was widespread or more localised in OA was 
still unknown. Hence, one of our research aims was to investigate joint effusion and synovitis 
at different anatomic sites. 
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Figure 1.5. The T2/PD weighted MR images show multiple synovial recesses in different 
subregions of a knee joint (53). 
(A) The central portion of the joint (arrow), between the patella and femoral shaft, extending 
medially and laterally deep to the patellar retinacula. The deep part of the central recess 
(arrow), around the ACL (B) and PCL (C). (D-E) The suprapatellar pouch, between the 
quadriceps tendon anteriorly and femur posteriorly (arrow), extending superiorly from the 
Central portion 
A B C 
Posterior femoral recess 
F G 
Suprapatellar pouch 
D E 
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upper surface of the patella. (F-G) The posterior femoral portions, above the lateral and 
medial sides of femur condyles (arrow).  
 
1.3.3 Biological markers 
In OA, inflammation occurs mainly in a restricted area of a periarticular joint. 
However, some biomarkers of inflammation can be detected in the circulation, especially in 
cases with generalised OA. For example, cartilage debris might trigger a systemic 
inflammatory response, leading to the release of pro-inflammatory mediators by the 
synovium. Also, the inflamed OA synovium itself could release synovial molecules (Table 
1.2).  
A high concentration of C-reactive protein measured using a high sensitivity assay 
(hs-CRP) was suggested to be predictive of rapid disease progression in early knee OA (61, 
62). It was positively associated with higher degree of inflammatory cell infiltration of the 
synovial tissue and also with higher levels of interleukin (IL)-6 in synovial fluid (63). In OA, 
the concentration of IL-6 in synovial fluid was positively correlated with the total leukocyte 
count (64). However, the effects of hs-CRP in predicting OA progression disappeared when 
other factors, such as age, BMI and serum IL-6, were taken into account (65). According to 
our recent meta-analysis, it remains inconclusive whether hs-CRP level could be a surrogate 
biomarker in OA, as it was correlated with clinical symptoms but not structural alterations 
(66). 
HA is an important component of articular cartilage, and the principle constitute of 
synovial fluid. HA is widely distributed throughout many body tissues, indicating its presence 
in the serum can be caused by conditions other than arthritis. When synovial alterations such 
as inflammation and hyperplasia occur, the permeability of the membrane is altered, which 
likely contributes to the decreased concentrations of HA and lubricin in synovial fluid. 
Hence, serum HA concentrations have been used as a marker of synovitis (67). An increase 
in serum levels of HA has been reported in patients with OA, but no correlation was found 
between serum levels of HA and CRP (68). A previous study has shown no correlation 
between serum levels of HA and the erythrocyte sedimentation rate (ESR) in patients with 
either hip or knee OA (69). The lack of associations supports the conceptualisation of HA as 
a marker of localised joint inflammation, as opposed to systemic inflammation. 
Serum levels of cartilage oligomeric matrix protein (COMP), a member of the 
thrombospondin family of glycoproteins, have been shown to be increased in individuals with 
Chapter 1 – Introduction   
 
 21 
knee OA and synovitis, compared to those without synovitis (70). Cartilage glycoprotein 39 
(CGP-39, also known as chitinase 3 like protein 1 and as YKL-40) is a 40 kDa glycoprotein 
secreted by chondrocytes and synoviocytes. Increased levels of CGP39 have been found in 
the synovial fluid and serum of patients with severe knee OA (71). Masuhara et al. has found 
the concentrations of matrix metalloproteases (MMPs) were elevated in the synovial cells, 
synovial fluid, plasma and serum in patients with rapidly destructive hip OA, a typical form 
of inflammatory OA (73). Finally, the secretion of glucosyl-galactosyl-pyridinoline (Glc-Gal-
PYD), a glycosylated analog of pyridinoline, which specifically reflects the degradation of 
synovial tissues, was also found increased in the urine sample of knee OA patients (74).
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Table 1.2. Biomarker related to synovium in osteoarthritis. 
Sources Observations Examples of related factors 
Serum/synovial fluid Increased levels of hs-CRP  
 Production and/or release of pro-inflammatory cytokines  TNF, IL-1β, IL-6, IL-8, IL-15, IL-17, IL-21 
 Production of adipokines visfatin, leptin, adiponectin 
 Decreased release of anti-inflammatory cytokines  IL-4, IL-10, IL-13, IL-1Ra 
 Increased activity of MMPs and ADAMTS  MMP-1, MMP-3, MMP-9, MMP-13 
 Increased production of PGE2 and nitric oxide  
 Release of growth factors EGF and VEGF 
 Release of pro-inflammatory and pain neurotransmitters Substance P, neuropeptide Y, NGF 
 Non-collagenous proteins CGP-39, HA 
Synovial tissue/cells Involvement of macrophages in osteophyte formation via BMPs  
 Increased levels of MMPs in synoviocytes MMP-3, MMP-9 
 Increased expression of adhesion molecules in the synovium ICAM-1, VCAM-1 
 Fragments of type II collagen and aggrecans  
 Other Other potential surrogate biomarkers of synovial inflammation   Glc-Gal-PYD 
Abbreviations: ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; BMP, bone morphogenetic protein; CGP-39, 
cartilage glycoprotein-39 (also known as chitinase-3-like protein 1 and YKL-40); CRP, C-reactive protein; EGF, endothelial growth factor; 
ICAM-1, intercellular adhesion molecule 1; IL, interleukin; IL-1Ra, interleukin 1 receptor antagonist; MMP, matrix metalloproteinase; NGF, 
nerve growth factor; PGE2, prostaglandin E2; TNF, tumor necrosis factor; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular 
endothelial growth factor. 
Chapter 1 – Introduction   
 
 23 
 
1.3.4 Clinical significance 
Research efforts have provided substantial evidence that synovial inflammation is 
associated with greater symptoms such as pain and degree of joint dysfunction, and may 
promote more rapid cartilage degradation and non-cartilaginous abnormalities.  
 
1.3.4.1 Association with symptoms 
Despite different approaches employed for detection and characterisation of synovitis 
(e.g. imaging or histologic assessment), evidence underpins the associations between 
synovial inflammation and knee symptoms in patients with OA. Torres et al. investigated the 
relationship between knee pain and specific joint pathology detected by MRI in OA patients. 
They noted that synovitis or effusion, meniscal tears, bone attrition and BMLs, were highly 
correlated with knee pain measured on a visual analog scale (VAS) (75). Others specifically 
examined the relationship between pain and MRI-detected synovitis and noted that changes 
in pain scores over time varied with changes in synovitis, strengthening the notion of a 
relationship (76, 77). Furthermore, there was a 9-fold greater risk of having painful knee OA 
conferred by higher grades of synovitis using contrast-enhanced (CE) MRI (78). We reported 
an independent association between effusion-synovitis using non-CE MRI and knee 
symptoms measured by the WOMAC score (which measures knee pain walking, climbing, 
sitting, standing and at night) in older adults with high risk of OA (Appendix 3). Among 
those associations non-weight-bearing pain was best correlated with synovial inflammation 
(79). The relationship between symptoms and synovitis was more likely to be localised to the 
infra-patellar and supra-patellar areas (80). There is conflicting evidence regarding 
association of pain with the severity of synovitis as determined on non-CE MRI (76, 81-85). 
Possible reasons for such discrepancies may include the use of different scoring methods for 
synovitis and pain, the use of different pulse sequences in different studies, and the limited 
specificity of signal alterations in Hoffa’s fat pad for detection of synovitis (86). 
Synovial inflammation has also been suggested to contribute in knee joint dysfunction 
using performance-based measures of walking and stair-climbing times (87). One study of 
patients receiving total knee replacement (TKR) with end-stage knee OA found that synovitis 
was closely correlated with the current functional impairment and disability (88). Despite 
some disagreements in the literature, the majority of available studies provide compelling 
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evidence that synovial inflammation is a rational target for therapeutic intervention to control 
joint symptoms in OA. Future work should help to define specific disease phenotypes or 
patient populations for whom targeting synovitis may have the greatest benefits. 
 
1.3.4.2 Association with structures 
The causal pathway of low-grade inflammation in non-osteochondral tissues and 
osteochondral abnormalities has become an emerging topic in recent years. Ayral et al. 
demonstrated that the progression of cartilage pathology was more advanced at one-year 
follow-up in patients with synovial inflammation. Approximately 50% of the patients had 
reactive (proliferation of opaque villi) or inflammatory (hyper-vascularisation and/or 
proliferation of hypertrophic and hyperemic villi) synovial abnormalities, which were 
documented by the visual appearance of the synovial membrane during baseline arthroscopy 
(89). There was also evidence to suggest that synovitis and/or effusion were predictors of 
progression to TKR in prospective studies (90, 91).  
However, the causal relationship between synovial inflammation and early 
osteoarthritic abnormalities was still inconclusive. A study of symptomatic OA patients failed 
to corroborate the associations between longitudinal changes in synovitis and cartilage (76). 
However, another study of early OA patients without radiographic changes has demonstrated 
that effusion and synovitis were associated with subsequent development of cartilage loss at 
30 months (92). A nested case-control study including patients with and without ROA has 
found that the occurrence of ROA was associated with the presence of effusion and/or 
synovitis at baseline and follow-up, supporting its role in predicting the development and 
incident of ROA (93). Our group has reported that in an older population with early stage of 
OA, effusion-synovitis not only independently predicted progression of cartilage defects over 
three years, but also preceded the worsening of subchondral BMLs (94). Miller et al. have 
demonstrated that knee effusion was associated with medial meniscal extrusion (95). 
However, a cross-sectional study of individuals who had or were at risk for knee OA reported 
that knee effusion was not associated with meniscal extrusion after adjusting for covariates 
(96). Another cross-sectional study reported that knees without OA but with meniscal 
pathology exhibited joint effusion to a significantly higher degree than those without 
meniscal damage. The association persisted for knees without cartilage damage. The 
prevalence of effusion is further increased when present in two compartments (97). It is 
suggested that the concomitant occurrence of synovial activation and early structural damage 
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may help to understand the pathophysiology of a degenerative joint disease at an early stage, 
but this needs longitudinal evidence to confirm.  
In addition to being a potential risk factor for knee OA, synovial inflammation is also 
thought to be triggered by release of detritus from cartilage and bone deteriorations 
throughout the course of OA (98, 99) . Once cartilage degradation has begun, the synovial 
cells phagocytose the breakdown products released into the synovial fluid, resulting in the 
synovial membrane becoming hypertrophic and hyperplasic. These enzymes then activate 
synovial cells to cause the release of pro-inflammatory cytokines, collagenases and other 
hydrolytic enzymes. Consequently, a vicious positive feedback loop involving cartilage 
breakdown and synovial inflammation occurs (100). 
Although the majority of published studies support a relationship between synovitis 
and joint structural damage, reasons for some disparate results are likely related to differences 
in patient populations, sample size, study time period as well as the methods and anatomical 
areas of assessing synovial abnormalities which will be introduced in the following section.  
 
1.3.5 MR Imaging assessment 
MRI-assessment of synovitis in knee OA is well-documented in the literature (53, 
101-105). The advantage of MRI over ultrasound and X-ray is that it can visualise synovial 
changes located deep within the joints without being obscured by bony structures.  
 
1.3.5.1 MRI methods 
MRI is uniquely able to directly depict all anatomic structures of the joint which has 
been increasingly recognised in OA research. MRI signs of synovial inflammation included 
increased synovial thickness/volume, increased signal intensity after intravenous gadolinium 
injection (enhancement), and increased water content (synovial effusion), alone or in 
combination (106). Non-CE MRI is still the most commonly used modality to assess 
synovitis in large epidemiological OA studies, although it has some limitations compared 
with CE MRI (78, 107-110). One distinct disadvantage of non-CE MRI is that it cannot 
differentiate inflamed synovium from joint effusion as shown in Figure 1.6. Only 
inflammatory synovium will manifest enhancement, while effusion will remain hypo-intense 
on T1-weighted sequences after contrast administration (111). Synovitis can be assessed 
indirectly using a surrogate marker in non-CE MRI, e.g. hyper-intense signal changes within 
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Hoffa’s fat pad on fat-suppressed (FS) proton density (PD) or T2-weighted fast spin echo 
(FSE) sequences which was shown in Figure 1.7 (112) (76, 113). Alternatively, synovitis can 
be evaluated in combination with effusion on these sequences, but inflamed synovium was 
not distinguishable from joint fluid filling the joint cavity surrounded by synovium because 
they both showed equivalent high signals (114, 115). Because of this, the phrase “effusion-
synovitis” has been proposed recently (Figure 1.8) (115).  
 
 
Figure 1.6. Joint effusion.  
(A) Axial PD FS image. Marked bright signal intensity within the joint and convexity of the 
joint capsule suggestive of a large joint effusion are depicted (arrowheads). (B) Axial T1 FS 
CE image of the same knee at the same slice position. The CE image shows marked synovial 
thickening depicted as hyper-intense tissue lining along the joint capsule. Only a small 
amount of effusion is observed (arrowheads) (111). 
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Figure 1.7. Synovitis in Hoffa’s fat pad.  
Equivalent delineation of hyper-intense signal changes in the infrapatellar (a and b, arrow) 
and intercondylar (a and b, arrowheads) regions. (a) Sagittal PD FS image at 1.0 T MRI. (b) 
Same slice on the 1.5 T system (112). 
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Figure 1.8. Joint effusion-synovitis.  
Hyper-intensity within the articular cavity represents a composite of effusion and synovial 
thickening that cannot be distinguished from each other in the absence of contrast. Grade 0 = 
none (A); grade 1 = small (B); grade 2 = medium (C) and grade 3 = large (D) (115). 
 
There are few studies using dynamic CE MRI, in which early enhancement (i.e. initial 
distribution of gadolinium) accurately reflects the inflammatory activity of the joint (106, 
116, 117). With static CE MRI, the extent of synovial enhancement may be misinterpreted if 
the assessment is performed on images acquired at a late phase. Because the signal intensity 
of joint effusion also enhances with time, as gadolinium passes into the joint space by 
diffusion of fluid from synovial capillaries (118). One study showed that dynamic CE-MRI 
with derived pharmacokinetic parameters can provide useful information in differentiating 
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synovitis in hand OA from rheumatoid arthritis (RA) (119). Another MRI-based study using 
a dynamic CE sequence found that quantitative synovial volume was strongly correlated with 
BMLs volume in knee OA patients (120). Thus, the clinical value of using dynamic CE T1-
weighted MRI to measure synovitis is required to assess in future OA studies. 
 
1.3.5.2 Assessment systems 
Several methods are available for semi-quantitative or quantitative assessment of 
effusion and/or synovitis in OA using non-CE and CE MRI (107, 108, 115, 121, 122). Semi-
quantitative scoring systems of knee OA that specify the synovial abnormalities are 
summarised in Table 1.3. 
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Table 1.3. Summary of semi-quantitative MRI scoring system for synovial abnormalities 
in knee OA.  
Author (year) Acronym Evaluation    Location Scores CE-MRI 
Kaneko (1993) - Effusion Central portion (para-ACL and para-PCL) 0-1 No 
   Suprapatellar pouch 0-1 No 
   Posterior femoral recess 0-1 No 
   Subpopliteal recess 0-1 No 
Hill (2001) - Effusion Joint cavity 0-3 No 
Peterfy (2004) WORMS 
Effusion/synovial 
thickening Joint cavity 0-3 No 
Loeullie (2005) MRI synovitis score Synovial thickening Medial and lateral suprapatellar recess 0-6 Yes 
   Trochlear groove 0-3 Yes 
   Medial and lateral femoral gutters  0-6 Yes 
Kornaat (2005) KOSS Effusion Joint recesses 0-2 Yes 
  Synovial thickening Synovial joint cavity 0-1 Yes 
Rhodes (2005) - Synovitis Para-patellar recesses 0-3 Yes 
Hunter (2008)  BLOKS Effusion Joint cavity 0-3 Yes 
  Synovitis Joint cavity 0-3 No 
Pelletier (2008) - Synovial thickening Medial and lateral recesses 0-6 No 
   Medial and lateral suprapatellar bursa 0-6 No 
Meredith (2009) - Effusion Joint cavity 0-3 No 
  Synovitis Joint cavity 0-3 No 
Baker (2010) - Synovial thickening Medial and lateral para-patellar recesses 0-3 Yes 
   Suprapatellar pouch 0-3 Yes 
   Infrapatellar fat pad 0-3 Yes 
   Medial and lateral posterior femoral condyles 0-2 Yes 
Baker (2010) WORMS  Effusion-synovitis Joint cavity 0-3 No 
Hunter (2011)  MOAKS Effusion-synovitis Joint cavity 0-3 No 
  Hoffa-synovitis Hoffa's fat pad 0-3 No 
Guermazi (2011) - Synovial thickening Medial and lateral para-patellar recesses 0-2 Yes 
   Suprapatellar 0-2 Yes 
   Infrapatellar 0-2 Yes 
   Intercondylar 0-2 Yes 
   Medial and lateral peri-meniscal 0-2 Yes 
   Adjacent to ACL/PCL 0-2 Yes 
Abbreviations: ACL: anterior cruciate ligament; PCL: posterior cruciate ligament; WORMS: Whole Organ Magnetic Resonance Imaging Score; 
KOSS: Knee Osteoarthritis Scoring Systems; BLOKS: Boston Leeds Osteoarthritis Knee Score; MOAKS: MRI Osteoarthritis Knee Score. 
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A histological correlation study comparing three scoring systems for evaluating 
synovitis and joint effusion on MRI reported that only the scoring from CE images correlated 
with microscopically proven synovitis (105). Studies have shown that effusion and synovitis 
often coexist in OA-affected joints but they seem to be two distinct entities (111, 113). Two 
studies reported that signal alterations in Hoffa’s fat pad seen on non-CE sequences were a 
sensitive (71-97%) but not a specific (10-55%) sign of peripatellar synovitis, compared with 
CE sequences (80, 86). A CE MRI-based study showed definite synovitis might be present 
independent of effusion (111). Also, in a non-ROA cohort, baseline joint effusion, but not 
synovitis, predicted the development of tibiofemoral cartilage loss (92). 
Rhodes et al. demonstrated that semi-quantitative scoring of OA synovitis using CE 
T1-weighted images was closely related to the quantitative synovial volume (107). This 
scoring method was subsequently modified and was used in another study which 
demonstrated that synovitis in the peri-patellar region had a strong correlation with knee pain 
severity (78). However, these evaluations were limited to synovitis of the peri-patellar region. 
Guermazi et al. have assessed synovitis at 11 sites of the entire knee joint in OA patients 
using CE MRI (108). It has shown that moderate to severe synovitis had a significant 
association with the maximum WOMAC pain score. More recently, the same group has 
reported that synovitis was strongly associated with tibiofemoral ROA and widespread MRI-
detected cartilage degradation (110). Another study by Roemer et al. has demonstrated an 
association between meniscal damage of the posterior horns and localised posterior synovitis 
(123). Moreover, synovitis severity evaluated using this scoring method was validated by 
arthroscopic and synovial biopsy findings in knee OA patients (124).  
There is a lack of longitudinal studies using MRI to evaluate changes in synovial 
inflammation before and after treatment. So far, there was only one RCT using CE MRI to 
monitor the efficacy of a bradykinin receptor-2 antagonist in symptomatic knee OA (125). 
Apart from a significant improvement in the VAS pain score after therapy, no significant 
change was observed in the severity of synovitis as detected on CE-MRI. Moreover, histo-
pathologic studies are needed to establish a better cut-off between physiologic and pathologic 
enhancement of synovial tissue (126, 127). To date, only three such studies have been 
published (88, 105, 109). There is still a lack of longitudinal studies using MRI to assess 
synovitis in knee OA and its relationship with progression of structural damage, such as 
cartilage loss and JSN. Current evidence regarding this was still inconsistent. Whether 
synovitis in knee OA predicts the progression of structural deteriorations is still inconclusive. 
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Since the synovial inflammation has a potential to regress, it would be a potential target in 
clinical practice and medical research. The following section will provide an overview of 
different treatments targeting on synovial inflammation. 
 
1.3.6 Synovial inflammation as a treatment target 
1.3.6.1 Developed strategies 
Classical non-targeted strategies, such as the use of NSAIDS, intra-articular injection 
or systemic administration of steroids, can modulate pain and function during both acute 
flares and chronic complaints in OA (128, 129). However, the complications caused by drug 
side-effects and repeated injections became problematic during long-term use. Some 
recommendations agree with the use of glycosaminoglycan (GAG) compounds like 
chondroitin sulfate (CS), glucosamine sulfate, and hyaluronic acid (HA). They are 
characterised by a delayed, but significant effect on pain and function in knee OA. 
Glucosamine and CS have been described as having disease-modifying effects in knee OA. 
 CS, a natural glycosaminoglycan, has demonstrated to control the 3 aspects of 
synovial inflammation: cell infiltration and action, biochemical mediators release and 
angiogenesis. In synovial fluid of patients requiring joint aspiration, treatment orally for 10 
days with CS (800 mg/day) significantly increased the hyaluronate concentration and the 
intrinsic viscosity, while decreased collagenolytic activity, phospholipase A2 and N-
acetylglucosaminidase (NAG) (130). In several arthritic animal models, CS has been found to 
significantly decrease the inflammatory and histo-pathological lesions of synovial membrane 
(131, 132). There is little information about the effect of CS in OA patients with moderate 
pain and manifestations of synovitis (joint swelling and effusion). The multicentre, double-
blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial 
(GAIT) assessed the effect of CS and glucosamine alone or in combination on joint swelling 
and/or effusion in 1583 patients with mild to severe knee OA (133). The patients received 
1200 mg of CS, or 1500 mg of glucosamine or both CS and glucosamine, or 200 mg of 
celecoxib or placebo, daily for 24 weeks. The results showed that CS diminished the 
percentage of patients with joint swelling and/or effusion from 28.3% at baseline to 12.4% at 
the end of 24 weeks of treatment. It is of interest that the beneficial effect of CS was 
statistically significant in the patients with mild pain (WOMAC pain scores 125-300). It has 
been suggested the direct anti-inflammatory effect on the synovium in OA, perhaps by 
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reducing the nuclear translocation of the transcription factor NF-κB in synoviocytes and 
macrophages thus decreasing inflammatory activation in these cells (130). 
Glucosamine, as a constituent of the natural glycosaminoglycan, can be provided to 
OA patients. It was first thought to be effective during cartilage repair by enhancing cartilage 
extracellular matrix components, such as aggrecan and collagen type II (134). Glucosamine 
has showed the potency of reducing synovial inflammation, including cell infiltration and 
hyperplasia (135). Interestingly, it inhibited IL-6 production, whereas up-regulated IL-10 in 
synovial inflammation of mouse collagen-induced arthritis (136). The anabolic properties of 
glucosamine were demonstrated in human OA synovial explants where it stimulated HA 
synthase activity and GAG production in human synovial cells (137, 138). The latest in vitro 
study showed glucosamine inhibited PGE2, nitric oxide (NO), and MMPs in synoviocytes, 
chondrocytes and macrophages (139) (140). Although there is a body of evidence supporting 
the anti-inflammatory effects of glucosamine in animal models and in vitro studies, clinical 
data supporting the effect of glucosamine on synovitis in OA patients are still lacking. 
It has been suggested that intra-articular injection of HA restores synovial fluid 
viscoelasticity, thus improves clinical symptoms and joint functionality (141). The anti-
inflammatory properties of HA consisted many cellular aspects of synovitis (141). In 
addition, HA was proven to reduce NO in synovial fluid of OA patients when concomitantly 
improving WOMAC pain and physical function scores (142). Moreover, the adhesion 
molecules induced by IL-1b, TNF-α and IFN, such as ICAM-1 and VCAM-1, were 
decreased in the synovial fluid of patients treated with HA (143). The number of lining cells, 
macrophages, lymphocytes, mast cells, and fibrin was also significantly reduced when 
examining synovial biopsies from OA patients 6 months after the last injection of HA (144). 
On the contrary, Schumacher et al. showed no differences in the severity of synovitis and the 
amount of synovial fluid between patients treated with and without HA, even if the treatment 
was proven to be beneficial on walking pain (145). This may be due to the short time between 
the examination and the last injection. Indeed, HA is known to have a long onset of action. 
Natural supplements have been advocated as novel treatments for OA recently. In 
vivo evidence reported that functional VDR signalling inhibited synovial inflammation, 
cartilage damage and bone erosion in arthritis by modulating monocyte function (146). 
Primary cultures of rheumatic synovial cells showed that VDR expression was found in the 
macrophages and fibroblasts. However, 25-(OH)D did not appear directly to affect the MMP 
or prostanoid production by unstimulated synovial fibroblasts or chondrocytes in vitro, rather 
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than through modulating the cytokine-induced MMP and PGE2 production (147). A RCT has 
shown that vitamin D supplementation significantly reduced serum levels of IL-6 and 
modulated adipokines in obese adolescents with low circulating 25-hydroxyvitamin D (25-
(OH)D) levels (148). Several epidemiological studies showed that lower serum levels of 25-
(OH)D were associated with higher prevalence of ROA (149, 150) and accelerated disease 
deteriorations (151-153). However, evidence remains controversial regarding the efficacy of 
vitamin D supplementation from limited OA trials. One study suggested it had beneficial 
effects on symptoms (154), while another showed no effects on symptoms and cartilage loss 
(155). Nevertheless, none of these studies has investigated the effects of vitamin D on 
synovial inflammation yet, leaving a window of opportunity in the future trial design. 
 
1.3.6.2 Developing strategies 
The synovial membrane is a promising target for novel strategies to prevent structural 
alterations and treat clinical symptoms (156). Designed to interfere with specific targets, the 
novel therapies include anti-fibrotic agents, biologic agents such as anti-TNF monoclonal 
antibodies, anti-NGF antibodies, anti-proteases (anti-MMPs and ADAMTS) and bradykinin-
blocking agents (157). Studies are underway to assess the effects of systemic TNF blocking 
agents in OA, although local IL-1 blockade has not been markedly beneficial (158). Data 
concerning the role of IL-6 in OA pathogenesis suggests that IL-6 targeted therapy could be 
an interesting approach for treating OA (159, 160). Specific aspects (e.g., control of 
inflammation and angiogenesis) could be identified when targeting synovitis in OA. 
 
1.4 Summary 
OA is a leading cause of disability among older adults, affecting one in eight adults 
(161). By 2050, the prevalence of OA is projected to increase to 11.2% of males and 14.5% 
of females, affecting nearly 3.8 million Australians (162). This highly prevalent disease and 
the attendant disability have a formidable effect on individuals and on society. Until recently, 
it has been recognised that cartilage damage is no longer the only initial pathologic feature in 
OA, while many non-cartilaginous structures are also involved. Synovial membrane, which 
contains metabolically highly active cells (synoviocytes), is physiologically important as it 
nourishes chondrocytes and removes metabolites of matrix degradation via the synovial fluid. 
Biomechanically, it lubricates the joint during movement and buffers the loading forces. As 
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synovial abnormalities are thought to occur at early stages of the disease, it could be an 
important risk factor in OA disease initiation and progression with a great potentially 
treatment value. 
The following chapters investigate the role synovial inflammation plays in knee OA 
using data from a cohort study of community-dwelling older adults and a RCT of knee OA 
patients with low vitamin D levels. Comprehensive analyses have been performed examining 
the associations between effusion-synovitis and measures of cartilage defect, cartilage 
volume loss, BML change, meniscal pathology, knee pain and function. Novel investigation 
about the therapeutic effects of vitamin D on synovial inflammation has been examined in 
knee OA patients. The following sections will provide an overview of the different synovial 
inflammation measures used in this thesis. 
The research questions, which directed this work, will be described in the next 
chapter. 
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In a population-based sample of community-dwelling adults who were aged 50–80 years 
examined at baseline and approximately 3 years later: 
1. What are the cross-sectional and longitudinal associations between MRI-detected 
regional effusion-synovitis and knee pain? 
2. What are the cross-sectional and longitudinal associations between MRI-detected 
regional effusion-synovitis and structural measures including cartilage defect, 
cartilage volume loss and BMLs? 
3. What is the natural history of MRI-detected effusion-synovitis and what structural 
factors are associated with the longitudinal change of effusion-synovitis? 
 
In a multicentre, randomised, placebo-controlled and double-blind clinical trial which was 
performed over 2 years in symptomatic knee OA patients with low vitamin D levels: 
1. What are the associations between disease outcomes and MRI-detected effusion-
synovitis using both quantitative and semi-quantitative measures? 
2. Does vitamin D supplementation have effects on MRI-detected effusion-synovitis 
volume? 
Chapter 3: Methodology   
 
 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 - Methodology 
  
Chapter 3: Methodology   
 
 39 
3.1 Prelude 
Chapter 4-6 in this thesis arose from analyses conducted in older adults, using data 
from the Tasmanian Older Adult Cohort (TASOAC) study. Chapter 7-8 arose from the 
analyses conducted in OA patients, using data from a randomised, placebo-controlled, and 
double-blind clinical trial (Vitamin D Effect on Osteoarthritis, VIDEO study). Both studies 
are similar in some aspects of methodology, particularly in the outcome factors, study factors 
and covariates. This chapter describes each study population and design, as well as the 
protocols for measurement of factors which are common to multiple chapters in this thesis. 
Additional factors which are unique to each chapter are described in more details within the 
methodology section of each of the subsequent chapters. 
 It should be noted that the following chapters are presented in the form in which they 
were submitted to, or accepted by, peer-reviewed journals for publication. Thus, throughout 
these chapters there are some differences in the description of methods, analyses, results, and 
interpretations, due chiefly to requests from journal reviewers.  
 
3.2 TASOAC study population and design 
The work in this thesis was conducted as part of the TASOAC study, an ongoing prospective, 
population-based study aimed at identifying the environmental, genetic, and biochemical 
factors associated with the development and progression of osteoarthritis (OA) at multiple 
sites (hand, knee, hip, and spine). The cohort consisted of both males and females aged 
between 50 and 80 years (mean ± standard deviation (SD) age = 62 ± 7 years), selected from 
the roll of electors in southern Tasmania (population 229,000) using stratified simple random 
sampling without replacement. Electoral rolls represent the most complete population 
information available in Australia because voting in federal and state elections is compulsory. 
The sample was stratified by sex to provide equal numbers of men and women, and equal 
distribution was drawn from urban and rural areas in southern Tasmania. As TASOAC was 
designed to examine community-dwelling older adults, institutionalised older adults were 
excluded. Participants were also excluded if they reported contraindication for MRI, as these 
tests were required to examine OA progression.  
Figure 3.1 provides an overview of participant recruitment and withdrawal during the 
study period. 2,135 initially eligible participants were identified from which 1,904 were able 
to be contacted. Of all initially eligible participants, 1,100 enrolled in the study, and 1,099 
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attended a baseline clinic between March 2002 and September 2004. The overall response 
rate for participation in Phase 1 is 57%, which is similar to response rates from studies with 
equivalent response burdens conducted around the same time period, such as the North West 
Adelaide Health Study at 58% (163), and the Australian Diabetes, Obesity and Lifestyle 
Study at 52% (164). Follow-up data was collected for 875 eligible participants (80%) at a 
subsequent clinic approximately 2.6 years later (range: 1.4-4.8 years). The MRI machine was 
decommissioned halfway through the follow-up period; therefore, MRI scans were only 
available for approximately half of the follow-up participants. As a result, the sample size 
used in Chapters 4–6 of this thesis varies depending on the available data for each of the 
research questions.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identified from roll of electors N = 2530 
Eligible at baseline N = 2135 
Eligible at follow-up N = 1099  
(Participation rate = 1099/2135 
=51.5%) 
Enrolled at baseline N = 1100 
(response rate = 1099/(2135-
231) = 57%) 
Ineligible N = 395 
Participated at follow-up 
(mean 2.6 ± 0.4 years later) 
N = 875 
(retention fraction 80%) 
Refused to participate N = 804 
Unable to contact N = 231 
Did not attend clinic N = 1 
Did not continue N = 224 
 
Untraceable N = 4 
Refused to participate N = 58 
Physically unable N = 15 
Institutionalised N =2 
Contraindication to MRI N = 85 
Joint replacement N = 14 
Moved away N = 15 
Deceased N = 15 
Other reasons N = 16 
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Figure 3.1. Flow chart describing recruitment, participation rates, and withdrawal 
reasons for TASOAC participants. 
 
3.2.1 Anthropometrics  
Each subject’s body weight was measured to the nearest 0.1 kg (with shoes, socks, 
and bulky clothing removed) using a single pair of electronic scales (Seca Delta Model 707, 
Bradford, MA, USA). Height was measured to the nearest 0.1 cm (with shoes and socks 
removed) using a stadiometer. BMI was calculated as kg/m2. 
 
3.2.2 Knee pain assessment 
Self-reported knee pain (walking on flat surface, going up/down stairs, at night in the 
bed, sitting/lying and stand upright) was assessed by knee-specific Western Ontario 
McMaster osteoarthritis index (WOMAC) (165). It was demonstrated in Appendix 2 with a 
10-point pain scale from 0 (no pain) to 9 (most severe pain). Total pain score (0-45) was 
created by summing all the subscale scores. 
The five WOMAC pain subscales were clinically categorised into weight-bearing pain 
(including pain on flat surface, on stairs and standing) and non-weight-bearing pain 
(including pain at night and sitting) as suggested by a previous study (166).  
The presence of knee pain was defined as a pain score of 1 or greater. Change in knee 
pain score was calculated as (follow-up value  baseline value), with a change in score of ≥ 
1 indicating increased knee pain (47). We have calculated the smallest statistically significant 
difference for the change in total WOMAC knee pain score (167) to be 0.8 for our 
population, so we defined an increase in pain as a change in score ≥ 1. 
 
3.2.3 Magnetic Resonance Imaging 
MRI of the right knee was acquired with a 1.5T whole-body magnetic resonance unit 
(Picker, Cleveland, OH, USA) using a commercial transmit/receive extremity coil. Image 
sequences included the following: (1) a T1-weighted fat saturation 3-dimensional (3D) 
gradient-recalled acquisition in the steady state, flip angle 30º, repetition time 31 ms, echo 
time 6.71 ms, field of view 16 cm, 60 partitions, 512  512–pixel matrix, acquisition time 5 
min 58 s, one acquisition; sagittal images were obtained at a slice thickness of 1.5 mm 
´
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without an inter-slice gap; and (2) a T2-weighted fat saturation two-dimensional (2D) fast 
spin echo, flip angle 90º, repetition time 3067 ms, echo time 112 ms, field of view 16 cm, 15 
partitions, 228  256–pixel matrix; sagittal images were obtained at a slice thickness of 4 
mm with an inter-slice gap of 0.5–1.0 mm. 
 
3.2.3.1 Effusion-synovitis 
Knee effusion-synovitis was assessed as the amount of intra-articular fluid-equivalent 
signal on T2-weighted MRI. We distinguish knee effusion-synovitis in 4 different subregions 
according to the anatomy of the joint synovial cavity (53). They are suprapatellar pouch: a 
large pouch is formed between the posterior suprapatellar fat pad (quadriceps femoris tendon) 
and the anterior surface of the femur; central portion: lies between the central femoral and 
tibial condyles, around the ligaments and menisci; posterior femoral recess: lies behind the 
posterior portion of each femoral condyle and the deep surface of the lateral and medial heads 
of the gastrocnemius; subpopliteal recess: lies posteriorly between the lateral meniscus and 
the popliteal tendon.  
i. Ordinal assessment for effusion-synovitis 
Effusion-synovitis in each subregion was scored individually according to WORMS, 
grading collectively from 0 to 3 in terms of the estimated maximal distention of the synovial 
cavity: 0 refers to normal; 1 to < 33% of maximum potential distention; 2 to 33% – 66% of 
maximum potential distention; 3 to > 66% of maximum potential distention (114). Figure 3.2 
demonstrates examples of the ordinal assessment. There is an obvious distention of the 
synovial cavity when effusion-synovitis of grade 2 is present, so pathological effusion-
synovitis was defined as any score of ≥ 2 (92). Total effusion-synovitis of the whole joint was 
defined as a score of ≥ 2 in any subregion. Two independent observers who scored all images 
were blinded to the patients’ information. The intraclass reliability assessed as weighted κ in 
50 randomly selected images were 0.63 – 0.75 in different subregions, and the interclass 
reliability were 0.65 – 0.79 (94) (expressed as weighted kappa 0.6=threshold for good 
validity (168)).  
´
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Figure 3.2. Typical T2-weighted fat-saturation fast spin echo sagittal images for effusion-
synovitis in different subregions.  
(A) Grade 3 effusion-synovitis in medial suprapatellar pouch (dash circle) and grade 2 central 
portion effusion-synovitis (solid circle); (B) grade 1 midline suprapatellar pouch effusion-
synovitis (dash circle) and grade 2 central effusion-synovitis around posterior cruciate 
ligament (solid circle); (C) grade 2 effusions in lateral posterior femoral recess (solid circle) 
and suprapatellar pouch (dash circle); (D) grade 2 subpopliteal effusion-synovitis (solid 
circle) around popliteal tendon (asterisk), extending to popliteal bursa (arrow). 
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ii. Areal assessment for effusion-synovitis 
 The size of effusion-synovitis (cm2) in each of subregions (referred as regions of 
interest, ROIs) was directly generated in the entire series of images using OsiriX software. A 
total area of all the ROIs in the same slice was summed as effusion-synovitis area of this 
slice. A maximal area in one slice was selected to represent effusion-synovitis area of the 
knee. A change in the effusion-synovitis area was calculated by subtracting baseline maximal 
area from follow-up maximal area (Figure 3.3). A musculoskeletal researcher (XW, 3 years 
experience) and an orthopaedic clinician (WH, 7 years experience) measured the maximal 
area of effusion-synovitis under the guidance of an experienced radiologist (AH, >20 years 
experience) and were blinded to the patients’ information. 100 randomly selected images 
were assessed with at least two weeks interval between the readings, and the intra-observer 
(expressed as the intraclass correlation coefficient, ICC) and inter-observer reproducibility 
was 0.81 and 0.60, respectively (169). 
The validity of effusion-synovitis maximal area measurement was tested by 
comparing this maximal area with total proxy volume generated using the OsiriX software in 
30 randomly selected participants (2-D sagittal T2-weighted images with inter-slice gaps did 
not allow calculating the real volume). There was a high correlation (r=0.83, p<0.001) 
between these two measures. We also compared the maximal area with semi-quantitative 
scores of effusion-synovitis, and found that the correlation was high (r=0.71, p<0.001). 
Changes in effusion-synovitis size were defined as increase, stable and decrease based on the 
least significant change criterion (LSC) (170), which takes into account measurement error 
and the correlation between the baseline and follow-up measurements. The formula was as 
follows: !"# = 1.96×* 2 1 − -  
(σ = the standard error of the mean; ρ = the serial correlation). 
LSC was calculated to be 0.49 cm2 (where σ = 0.3419 and ρ = 0.7328) in this study. 
Therefore, an increase in effusion-synovitis size was defined as a change in effusion-
synovitis area of ≥ 0.49 cm2. A decrease in effusion-synovitis size was defined as a change in 
effusion- synovitis area of ≤ −0.49 cm2. 
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Figure 3.3. Examples of changes in effusion-synovitis area (cm2).  
Effusion-synovitis size decreased from baseline to follow-up (A-B) or increased from 
baseline to follow-up (C-D). The ROIs included suprapatellar pouch (ROI-1), central portion 
(ROI-2), posterior femoral recess (ROI-3) and subpopliteal recess (ROI-4). 
iii. Voluminal assessment for effusion-synovitis 
 Each subregion of effusion-synovitis was also measured the maximum area of the 
lesion as demonstrated in Figure 3.4. The volumes of individual joint subregions were 
isolated from the total volume by selecting each region of interest (ROI) according to the 
intra-articular fluid-equivalent signal on a section-by-section basis. The final 3-D volume 
rendering was generated using commercial in-house OsiriX Lite imaging software cursors 
(32-bit version 5.9, Pixmeo SARL, Geneva, Switzerland) (171) (Figure 3.4). The readers 
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were blinded to the treatment allocation and patients’ information. To analyse the reliability 
of measurement, two independent readers assessed 40 randomly selected images with at least 
a 4-week interval between readings. The intra-class correlation coefficients (ICCs) were 0.96-
0.97 and inter-rater correlation coefficients were 0.93-0.99 in different subregions. 
Change in effusion-synovitis volume was calculated as follows: Absolute change (ml) 
= (follow-up volume) – (baseline volume); Relative change per annum (%p.a.) = [(absolute 
change)/(baseline volume)]/(time interval between 2 scans) x 100.  
The semi-quantitative increase or decrease was defined by LSC as previously 
described (e.g., an increase in effusion-synovitis volume was defined as a change in effusion-
synovitis volume of ≥ 1.81 ml; and a decrease in effusion-synovitis volume was defined as a 
change ≤ -1.81 ml). The minimal clinically important difference (MCID) was estimated for 
effusion-synovitis volume (both the absolute and the relative annual change). A reduction of 
mean WOMAC function score ≥ 7 was used as an anchor to determine the cut-off of 
effusion-synovitis volume in patients who actually experienced clinically significant 
improvement (167). 
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Figure 3.4. MRI acquired from the knee, with superimposed colour data showing the area 
of high signal. 
The images were obtained before (A) and 24 months after (B) intervention. Data were 
analysed in two regions of interests (ROIs), which were located in the suprapatellar pouch 
(ROI-1, pixels shown in green) and the central joint cavity (ROI-2, pixels shown in red), 
respectively. The total volume was generated from the area of each ROI in the entire series of 
images using OsiriX software (C). 
 
3.2.3.2 BMLs 
 Subchondral BMLs were assessed on T2-weighted MR images using OsiriX software 
and were defined as areas of increased signal adjacent to the subcortical bone at the medial 
A 
ROI-1: Suprapatellar pouch 
Total&volume:&43.83&ml&
B 
ROI-1: Suprapatellar pouch 
Total&volume:&3.19&ml&
ROI-2: Central cavity ROI-2: Central cavity 
C 
Total&volume:&88.22&ml&
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tibial, medial femoral, lateral tibial, and lateral femoral sites. BMLs were scored using both 
an ordinal scoring system and an areal scoring system. Each BML was scored on the basis of 
lesion size (e.g. a lesion was scored as grade 1 if it was only present on one slice, grade 2 if 
present on two consecutive slices, or grade 3 if present on 3 or more consecutive slices). The 
BML with the highest score was used if more than one lesion was present at the same site. 
Intra-observer repeatability was assessed in 50 subjects with at least a one-week interval 
between the two readings. The intraclass correlation coefficients (ICCs) were 0.94, 1.00, 
0.89, and 0.96 at the medial tibial, medial femoral, lateral tibial, and lateral femoral sites, 
respectively (172). 
3.2.3.3 Cartilage defects 
Cartilage defects were assessed on T1 and T2-weighted MR images (score range, 0–
4) at the medial tibial, medial femoral, lateral tibial, and lateral femoral sites, as previously
described (173) as follows: grade 0 = normal cartilage; grade 1 = focal blistering and intra-
cartilaginous low or high-signal intensity area with an intact surface and base;
grade 2 = irregularities on the surface or base and loss of thickness <50%; grade 3 = deep
ulceration with loss of thickness >50%; and grade 4 = full-thickness chondral wear with
exposure of subchondral bone. A cartilage defect also had to be present on at least two
consecutive slices. The cartilage was considered to be normal if the band of intermediate
signal intensity had a uniform thickness. The highest score was used if more than one defect
was present on the same site. One observer scored the cartilage defects.
Intra-observer repeatability was assessed in 50 subjects with an interval of at least one 
week between the two measurements. ICCs were 0.93, 0.92, 0.95, and 0.80 at the medial 
tibia, medial femur, lateral tibia, and lateral femur, respectively.  
3.2.3.4 Cartilage volume 
Knee tibial cartilage volume was assessed on T1-weighted MR images by means of 
image processing on an independent workstation using OsiriX software as previously 
described (47). The volumes of individual cartilage plates (medial tibia and lateral tibia) were 
isolated from the total volume by manually drawing disarticulation contours around the 
cartilage boundaries on a section by section basis. These data were then resampled by means 
of bilinear and cubic interpolation (area of 312  312 mm and 1.5 mm thickness, continuous ´
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sections) for the final 3D rendering. The CV in our hands for this method of measurement 
was 2.1% for the medial tibia and 2.2% for the lateral tibia (47). 
 
3.2.3.5 Meniscal pathology 
Meniscal lesions were assessed by a trained observer on MR images as previously 
described (47, 174). The proportion of the menisci affected by a tear, partial or full extrusion 
was scored laterally and medially at the anterior horn, body, and posterior horn. These scores 
were summed to create a total meniscal pathology score (47).  
 
3.2.3.6 Tibial bone area 
Knee tibial plateau bone area was assessed on T1-weighted MR images and defined 
as the cross-sectional surface area of the tibial plateau, as previously described (29, 73, 117). 
Medial and lateral bone area was measured manually by reformatting the whole sagittal 
image to the axial plane. The area was then measured on 3 slices closest to the tibial cartilage 
and the mean of all 3 areas was used as an estimate of the tibial plateau bone area. The slice 
thickness on the axial images was 0.625 mm. In a previous study, the coefficient of variation 
(CV) in our hands for this method of measurement was 2.2–2.6% (47).  
 
3.2.4 X-ray 
A standing anteroposterior semi-flexed view of the right knee with 15° of fixed knee 
flexion was performed. Radiographs were assessed using the atlas developed by Altman et al 
(175). Each of the followings was assessed on a scale of 0–3: medial JSN, lateral JSN, medial 
femoral osteophytes, medial tibial osteophytes, lateral femoral osteophytes, and lateral tibial 
osteophytes. Each score was determined by consensus of two readers who simultaneously 
assessed the radiograph with immediate reference to the atlas. Intra-observer repeatability 
was assessed in 40 subjects with an interval of at least one week between the two 
measurements. ICCs ranged from 0.65 – 0.85. The presence of ROA was defined as any 
score ≥1 for JSN or osteophytes (172).   
Chapter 3: Methodology   
 
 50 
3.2.5 Summary of outcome factors, study factors, and covariates 
Table 3.1 summarises the variables used in each chapter of this thesis.   
Table 3.1. Summary of outcome factors, study factors, and covariates used in this thesis. 
 
Chapter 
 
 
Outcome factors 
 
Study factors 
 
Covariates 
4 Pain Effusion-synovitis Age, sex, BMI, ROA, cartilage 
defects, BMLs, meniscal lesions 
5 Cartilage defects, 
cartilage volume, 
BMLs  
Effusion-synovitis Age, sex, BMI, cartilage defects, 
cartilage volume, bone area, 
BMLs, ROA 
6 Effusion-synovitis  
 
Cartilage defects, cartilage volume, 
BMLs, meniscal lesions, osteophytes, 
JSN 
Age, sex, BMI, bone area, ROA 
*Measurement protocol described in “Materials and Methods” section of the relevant chapter. 
 
3.2.6 Ethical considerations 
All procedures in TASOAC were approved by the Southern Tasmanian Health and 
Medical Human Research Ethics Committee (Ethics Approval Number: H6488). Written 
informed consent was obtained from all participants prior to enrolment in the study. 
 
3.2.7 Statistical analysis 
T-tests and chi-squared tests were used to compare differences in means and 
proportions as appropriate. Standard diagnostic checks of model fit and residuals were 
routinely performed, and data points with large residuals and/or high influence were 
investigated for data errors. A p value less than 0.05 (two-tailed) is considered statistically 
significant. A more detailed description of statistical analyses performed is presented in their 
relevant chapters. All statistical analyses were performed on Intercooled Stata versions 12 or 
13 for Mac (StataCorp., College Station, USA). 
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3.3 VIDEO Study population and design 
The work in this thesis was conducted as part of the VIDEO study, a randomised, 
double-blind, placebo-controlled clinical trial primarily aimed at determining whether 
vitamin D supplementation reduces the loss of knee cartilage volume (~2% per year less loss 
than placebo group) and progression of knee pain in symptomatic knee OA patients (176). 
Participants were recruited in Tasmania and Victoria, Australia, using a combined strategy, 
including working with general practitioners, specialist rheumatologists and orthopaedic 
surgeons, and advertising through media and community groups. Eligible participants were 
randomly allocated to either treatment or matching placebo group in a 1:1 ratio. A telephone 
pre-screen assessed knee pain, anticipated knee and hip surgery, participation in other studies 
and comorbidities. Eligible participants were subsequently screened in a clinic visit including 
knee radiographs and a blood test for serum 25-(OH)D level.  
Eligible participants were aged between 50 to 79 years with symptomatic knee OA for 
at least 6 months and pain of at least 20 mm on a 100 mm on a visual analogue scale (VAS) 
and were recruited from August 2010 to December 2011. All individuals were assessed 
according to the American College of Rheumatology (ACR) criteria for symptomatic knee 
OA (4). Participants also had an ACR function class rating of I, II and III (177) and relatively 
good health, with a score of 0 to 2 on a 5-point Likert scale (from 0 indicating very good 
health to 4 indicating very poor health) according to the global investigator assessment of 
disease status. Participants were included if their serum 25-(OH)D levels > 12.5 nmol/l or < 
60 nmol/l. Exclusion criteria included grade 3 knee ROA according to Altman’s atlas (175), 
contraindication to MRI, rheumatoid or psoriatic arthritis, lupus, cancer, severe cardiac or 
renal impairment, hypersensitivity to vitamin D, conditions affecting oral drug absorption, 
anticipated knee or hip surgery within the next two years, history of significant trauma of 
knees (e.g. arthroscopy or injury to ligaments or menisci within one year preceding the study) 
and history of taking vitamin D or an investigational drug within the last 30 days. 
Figure 3.5 provides an overview of participant recruitment and withdrawal during the 
study period. A total of 599 participants were screened for eligibility and 413 subjects were 
randomly assigned to either the vitamin D or the placebo group. Over 24 months, 28 (13.4%) 
in the vitamin D group and 45 (22.1%) in the placebo group withdrew from the study. A total 
of 340 patients (82.3%) completed the follow-up. The number of patients who discontinued 
treatment allocation was larger in the placebo group than the vitamin D group (21 versus 8). 
The major reason for discontinuation was non-adherence to the protocol when low 25-(OH)D 
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levels were disclosed to the participants by their general practitioners. Intention-to-treat 
analyses were performed in all 413 randomised participants. The mean age of participants 
was 63.2 ± 7.0 years, with 208 (50%) females and a mean BMI of 29.6 ± 5.0 kg/m2.  
Figure 3.5. Flow chart describing recruitment, participation rates, and withdrawal 
reasons for VIDEO participants. 
3.3.1 Intervention 
Participants in the intervention group were given a monthly capsule of 50,000 IU 
(1.25 mg) vitamin D3 (cholecalciferol) for 24 months (178). The vitamin D3 compound was 
purchased from Nationwide Compounding Pharmacy, Melbourne, Australia. Participants in 
the control group received an identical inert placebo provided by the same company. 
3.3.2 Randomisation 
Participants were allocated to either vitamin D or placebo arm at a ratio of 1:1 based 
on computer-generated random numbers. Allocation concealment was ensured by a central 
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automated allocation procedure with security in place to ensure allocation data cannot be 
accessed or influenced by any person from the investigative team. 
 
3.3.3 Blinding 
Participants, research coordinators and investigators were all blinded to treatment 
assignment. The blinding procedure was maintained until all the data were collected, cleaned, 
confirmed for accuracy and statistical analyses were performed. 
 
3.3.4 Trial monitoring and safety assessments 
The project manager visited and monitored each site to examine trial procedures, 
ensure data quality and compliance with the trial protocol. Spontaneously reported adverse 
events were recorded throughout the study. Intensity and relationship with the study 
medication were ascribed. 
 
3.3.5 Anthropometrics  
Height and weight were measured as described in section 3.2.1, and BMI was 
calculated.  
 
3.3.6 Knee symptoms 
Knee symptoms were assessed from baseline to month 24, using the WOMAC score 
as described in section 3.2.2. The WOMAC system quantifies the degree of pain (5 
questions), functional impairment (17 questions) and stiffness (2 questions) in patients with 
OA. Each question was assessed in a 100 mm visual analogue format to create a total score 
(179). 
 
3.3.7 Magnetic Resonance Imaging 
T1 and T2 weighted MRI scans were taken using the same protocol as described in 
section 3.2.3. Proton density-weighted coronal fat-suppressed, FSE, flip angle 90°, repetition 
time 2640 msec, echo time 37 msec, FOV 16 cm, 30 slices, 256 × 256-pixel matrix, 
acquisition time 5 min 26 sec, 1 acquisition, slice thickness of 3 mm. 
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3.3.7.1 Effusion-synovitis 
Knee effusion-synovitis was assessed on T2-weighted and proton density-weighted 
MR images, as previously described in section 3.2.3.1 . 
As the MRI sequence used to determine effusion-synovitis at the site in Victoria was 
obtained in the coronal plane, the subregional effusion-synovitis was unable to be 
differentiated in Victorian participants. Hence, subregional analyses were only performed in 
participants from Tasmania. 
 
3.3.7.2 BMLs 
 BMLs were assessed on T2-weighted MR images as previously described in section 
3.2.3.2 . 
 
3.3.7.3 Cartilage defects 
Cartilage defects were assessed on T1 and T2-weighted MR images as previously 
described in section 3.2.3.3 . 
 
3.3.7.4 Cartilage volume 
Tibial cartilage volume was assessed on T1-weighted MR images as previously 
described in section 3.2.3.4 . 
 
3.3.7.5 Tibial bone area 
Tibial plateau bone area was assessed on T1-weighted MR images as previously 
described in section 3.2.3.6 . 
 
3.3.8 X-ray 
A Knee x-rays were obtained and scored for JSN and osteophytes using the same 
protocol as described in section 3.2.4. 
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3.3.9 Serum 25-(OH) D 
Serum 25-(OH)D was assayed by Liaison method utilising a direct competitive 
chemiluminescent immunoassay (DiaSorin Inc., Stillwater, Minnesota, USA). The intra-assay 
and inter-assay CVs were 3.2% and 6.0%. 
 
3.3.10 Summary of outcome factors, study factors, and covariates 
Table 3.2 summarises the variables used in each chapter of this thesis.   
Table 3.2. Summary of outcome factors, study factors, and covariates used in this thesis 
 
Chapter 
 
 
Outcome factors 
 
Study factors 
 
Covariates 
7 Effusion-synovitis Pain*, function*, stiffness*, cartilage defects, 
cartilage volume, BMLs 
Osteophytes 
JSN 
Age, sex, BMI, ROA, 
study site, 25-(OH)D* 
 
8 Effusion-synovitis Vitamin D or placebo effect* -- 
*Measurement protocol described in “Materials and Methods” section of the relevant chapter. 
 
3.3.11 Sample size and role of the candidate in the VIDEO study 
As the TASOAC study was in progress before the commencement of the Ph.D. 
candidature formal sample size calculations were not performed during the design of this 
thesis. The statistical power calculation is based on formula provided by Cohen (180). Using 
primary outcome cartilage volume loss in the VIDEO study, the sample size was calculated 
as 200 per group (176). From our previous study in older people with knee pain, 29% of 
participants experienced an increase in effusion-synovitis size (181). With 400 recruited 
patients (200 in each arm), we have 80% power (α=0.05) to detect a 13% difference in the 
increase in effusion-synovitis size.  
Whilst the candidate was involved in VIDEO data acquisition during candidature, 
data acquisition was also completed prior to and during the candidature by a number of other 
VIDEO staff and volunteers, including Changhai Ding, Graeme Jones, Flavia Cicuttini, Anita 
E Wluka, Tania Winzenberg, Jodi Barling, Kay Nguo, Benny Antony, Yuelong Cao, Judy 
Hankin and Alice Noone. The candidate gratefully acknowledges the efforts of Xingzhong 
Jin in cleaning the vitamin D data, cartilage volume, cartilage defect, BMLs and bone area 
data; Weiyu Han and Zhaohua Zhu in measuring of radiographic data. 
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3.3.12 Ethical considerations 
Ethics approval was received from the Tasmania Health and Human Medical 
Research Ethics Committee (reference number H1040) and Monash University Human 
Research Ethics Committee (reference number CF10/1182-2010000616). Informed written 
consent was obtained from all participants. 
 
3.3.13 Trial registration 
ClinicalTrials.gov identifier: NCT01176344;  
Australian New Zealand Clinical Trials Registry: ACTRN12610000495022. 
 
3.3.14 Protocol 
Cao Y, Jones G, Cicuttini F, et al. Vitamin D supplementation in the management of 
knee osteoarthritis: study protocol for a randomized controlled trial. Trials 2012;13:1. 
 
3.3.15 Statistical analysis 
All statistical analyses were performed similarly as described in section 3.2.7.  
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Chapter 4 – Regional knee effusion-synovitis and knee pain in older adults: 
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Chapter 5 - Regional knee effusion-synovitis and knee structural 
abnormalities in older adults: a cohort study 
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5.1 Introduction 
OA is characterized by joint pain and structural changes including cartilage loss and 
subchondral bone abnormalities. Synovial activation, namely proliferation and inflammation, 
has emerged as a critical component of OA and a potential predictor of disease progression 
(89). It has been linked to the signs of disease flare-up, such as joint swelling and 
inflammatory pain (100), though not all consistent (77, 83). 
Synovial inflammation can occur at both the early and late stages of OA (51). In vitro 
and animal studies have demonstrated that inflamed synovium produces catabolic and pro-
inflammatory mediators such as cytokines, nitric oxide, prostaglandin E2 and neuropeptides, 
which lead to excess production of the proteolytic enzymes responsible for cartilage 
breakdown, disturbing the homeostasis of cartilage matrix degradation and repair (206, 207). 
Cartilage breakdown products in turn exacerbate synovial inflammation, creating a vicious 
circle (208). These suggest that synovial inflammation can be a cause or a result of knee 
structural changes; however, epidemiological and clinical studies have shown inconsistent 
associations between synovial inflammation and knee focal cartilage loss (76, 92, 209). It is 
not known whether synovial inflammation is associated with diffuse cartilage loss assessed 
by cartilage volume and subchondral bone abnormalities such as BMLs, and whether 
synovial inflammation is causally related to these structural changes.    
Clinically, synovial pathology is usually manifested as thickening of synovium 
(synovitis) and/or excess synovial fluid (effusion) (185), which are usually assessed as a 
whole according to the extent of capsular distention using non-contrast-enhanced magnetic 
resonance imaging (MRI) (111). To date, it is still unknown whether effusion/synovitis is 
distributed in a homogeneous fashion within the joint cavity. It is also unclear whether 
effusion/synovitis in different anatomical subregions have different impacts on intra-articular 
pathology. MRI is able to detect minor effusion/synovitis in the whole joint, which allows us 
to determine whether effusion/synovitis in different locations is associated with MRI-detected 
osteoarthritic alterations. The aim of this study, therefore, was to describe the cross-sectional 
and longitudinal associations between knee regional effusion-synovitis and structural changes 
in older adults. 
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5.2 Materials and Methods  
5.2.1 Participants and study design 
This study used subjects from the TASOAC study as described in section 3.2. 
 
5.2.2 Knee MRI sequences 
T1 and T2 weighted fat saturated MRIs sequences as described in section 3.2.3. 
 
5.2.3 Knee MRI measurements 
5.2.3.1 Effusion-synovitis 
Baseline effusion-synovitis was scored in four subregions as described in section 
3.2.3.1 and displayed in Figure 3.2. 
 
5.2.3.2 Cartilage volume 
Baseline and follow-up cartilage volume was measured on MRI as described in 
section 3.2.3.4 . 
 
5.2.3.3 Cartilage defects 
Baseline and follow-up cartilage defects were assessed from 0-4 on MRI as described 
in section 3.2.3.3 . 
 
5.2.3.4 BMLs 
Baseline and follow-up BMLs were assessed from 0-3 on MRI as described in section 
3.2.3.2 . 
 
5.2.3.5 Tibial bone area 
Baseline and follow-up tibial bone area was measured on MRI as described in section 
3.2.3.6 . 
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5.2.4 Knee X ray 
Baseline knee radiographs were taken and scored for ROA as described in section 
3.2.4. 
5.2.5 Anthropometrics 
Height, weight and BMI was measured as previous described in section 3.2.1. 
5.2.6 Statistical analysis 
Comparisons of baseline characteristics by effusion-synovitis status were carried out 
using unpaired student t-tests or chi-square tests (as appropriate). The statistically significant 
differences between subjects who completed the study and who were lost to follow-up were 
evaluated using t-test or chi-square tests (as appropriate).  
We examined the associations between effusion-synovitis and baseline/change in 
cartilage volume using linear regression. Logistic regression analysis and generalized linear 
models were used to estimate prevalence ratios (PR) or relative risks (RR) (195) between 
effusion-synovitis and JSN, osteophytes, cartilage defects and BMLs. The associations were 
adjusted for age, gender, BMI, and ROA, and further adjusted for tibial bone area (for 
cartilage volume), cartilage defects and/or BMLs (where appropriate). Standard diagnostic 
checks of model fit and residuals were routinely performed, and data points with large 
residuals and/or high influence were investigated for data errors. Interactions between gender 
or ROA, and effusion-synovitis were investigated by testing the statistical significance of the 
coefficient of a product term (effusion ×gender or ROA) after adjustment for confounders.  
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5.3 Results  
5.3.1 Characteristics of participants 
At baseline, 977 subjects (50% females) were included in this study. The average age 
was 62.3 years, and the mean BMI was 27.7 kg/m2. Prevalence of knee joint effusion-
synovitis (≥2) was 67% in the whole joint cavity (42.9% in suprapatellar pouch, 48.8% in 
central portion, 10.3% in posterior femoral recess and 14.4% in subpopliteal recess). As 
shown in Table 5.1, participants with or without effusion-synovitis (score 0-1 vs. 2-3) were 
similar in terms of gender, BMI, ROA, total cartilage volume and BMLs; however, 
participants with effusion-synovitis were older, had larger tibial bone size, and had higher 
proportions with osteophytes and cartilage defects. 
Over 2.7 years (range from 1.3 to 4.8 years), 115 subjects did not continue at follow-
up because of death (n=28), joint replacement (n=15), being physically unable (n=28), 
moving away (n=20) and other reasons such as refusing to continue or giving no reason. In 
subjects who completed the follow-up study, the first 404 subjects had the second MRI scan, 
but the others did not because the local MRI machine was decommissioned and became 
unavailable for research purposes. There were no significant differences in demographic 
factors, including age, gender, BMI and diseases status, between participants who remained 
in the study and who dropped out. There were no significant interactions between 
demographic factors and effusion-synovitis on joint structural changes. 
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Table 5.1. Characteristics of sample at baseline. 
Characteristics  
Knee effusion-synovitis 
Absent (Grade 0-1) 
N=323 
Present (Grade 2-3) 
N=654 
p value 
Age 61.14 (7.03) 62.90 (7.47) <0.01 
Female (%) 53 49 0.28 
Body mass index 27.55 (4.32) 27.84 (4.84) 0.37 
Tibial bone area (ml) 3.26 (0.48) 3.37 (0.50) <0.01 
Total cartilage volume (ml) 8.29 (1.98) 8.28 (1.95) 0.94 
Knee radiographic osteoarthritis (%) 58 60 0.51 
Any joint space narrowing (%) 57 60 0.41 
Any osteophytes (%)	 8 13 0.01 
Any cartilage defect (%)	 47 61 <0.01 
Any bone marrow lesion (%) 26 32 0.27 
Two-tailed t-tests are used for differences between means; chi-square tests are used for proportions. 
Results are shown as mean (SD) or percentage. Data in bold denote statistically significant results. 
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5.3.2 Effusion-synovitis and cartilage defects 
Cross-sectionally, knee effusion-synovitis in all of the subregions, including 
suprapatellar pouch, central portion, posterior femoral recess and subpopliteal recess, was 
significantly associated with cartilage defects in multivariable analyses (Table 5.2). The 
significant associations apart from that in central portion remained significant after further 
adjustment for BMLs (Table 5.2). 
 Longitudinally, effusion-synovitis in whole knee joint and 2 joint subregions (except for 
central portion and posterior femoral recess) was significantly associated with worsening 
cartilage defects and remained significant after further adjustment for baseline BMLs and 
cartilage defects (Table 5.2). There was a dose-response association between suprapatellar 
pouch effusion-synovitis and an increase in cartilage defects (Figure 5.1A). 
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Table 5.2. Associations between knee effusion-synovitis and cartilage defects. 
 Multivariable*  Multivariable**  
Baseline cartilage defects PR (95%CI) PR (95%CI) 
Whole knee joint 1.21 (1.11, 1.31) 1.15 (1.06, 1.25) 
Suprapatellar pouch 1.18 (1.10, 1.27) 1.13 (1.05, 1.22) 
Central portion 1.11 (1.02, 1.20) 1.06 (0.97, 1.15) 
Posterior femoral recess 1.18 (1.00, 1.39) 1.18 (1.01, 1.39) 
Subpopliteal recess 1.17 (1.07, 1.28) 1.14 (1.04, 1.24) 
Any increase in cartilage defects RR (95%CI) RR (95%CI) 
Whole knee joint 1.13 (1.03, 1.25) 1.11 (1.01, 1.23) 
Suprapatellar pouch 1.23 (1.12, 1.34) 1.19 (1.09, 1.31) 
Central portion 1.01 (0.91, 1.12) 1.01 (0.91, 1.12) 
Posterior femoral recess 1.05 (0.85, 1.29) 1.03 (0.84, 1.27) 
Subpopliteal recess 1.23 (1.14, 1.34) 1.20 (1.10, 1.30) 
Dependent variable: baseline and increase in cartilage defects (yes vs. no). Independent variable: knee 
effusion-synovitis (per grade).  
*Adjusted for age, gender, BMI and radiographic osteoarthritis. **Further adjusted for baseline bone 
marrow lesions and cartilage defects (for longitudinal analyses only). 
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Figure 5.1. Longitudinal associations between joint effusion-synovitis in suprapatellar 
pouch and structural measures over 2.6 years. 
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(A) Increases in cartilage defects (%) (B) Changes in cartilage volume per annum (%) (C)
Increases in bone marrow lesions (%). Number of participants in each grade: N= 51 (grade0-
1), N=74 (grade 2), N = 27 (grade 3) * p values were those after adjustment for baseline age,
gender, BMI and radiographic osteoarthritis.
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5.3.3 Effusion-synovitis and cartilage volume 
Cross-sectionally, effusion-synovitis in whole joint, suprapatellar pouch and posterior 
femoral recess was negatively and significantly associated with total tibial cartilage volume 
after adjustment for age, gender, BMI, ROA, bone area and BMLs (Table 5.3). These 
associations became non-significant after further adjustment for cartilage defects (Table 5.3). 
Effusion-synovitis in central portion and subpopliteal recess was not significantly associated 
with total cartilage volume (Table 5.3). 
Longitudinally, effusion-synovitis in suprapatellar pouch was significantly associated 
with change in cartilage volume after adjustment for age, gender, BMI and ROA (Table 5.3). 
Grade 2 and 3 suprapatellar pouch effusion-synovitis was associated with greater loss of 
cartilage volume than grade 1 effusion-synovitis (Figure 5.1B). The magnitude of association 
decreased by 11% and became of borderline significance (p=0.07) after further adjustment 
for baseline cartilage volume, tibial bone area and BMLs (Table 5.3) (decreased by 7% after 
sole adjustment for BMLs). The magnitude of association decreased by a further 17% after 
adjustment for cartilage defects (Table 5.3). Effusion-synovitis in other subregions was not 
significantly associated with change in knee cartilage volume (Table 5.3). 
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Table 5.3. Associations between knee effusion-synovitis and cartilage volume. 
Multivariable* Multivariable** Multivariable# 
Baseline cartilage volume β (95%CI) β (95%CI) β (95%CI) 
Whole knee joint -0.11 (-0.24, 0.01) -0.16 (-0.28, -0.04) -0.07 (-0.18, 0.04)
Suprapatellar pouch -0.15 (-0.28, -0.02) -0.20 (-0.32, -0.08) -0.08 (-0.19, 0.04)
Central portion -0.05 (-0.18, 0.09) -0.05 (-0.18, 0.08) -0.02 (-0.13, 0.10)
Posterior femoral recess -0.32 (-0.62, -0.03) -0.37 (-0.64, -0.10) -0.21 (-0.46, 0.05)
Subpopliteal recess -0.11 (-0.30, 0.07) -0.10 (-0.27, 0.07) 0.01 (-0.14, 0.17)
Changes in cartilage volume (% 
p.a.)
Whole knee joint -0.16 (-0.67, 0.34) -0.12 (-0.62, 0.38) -0.03 (-0.53, 0.48)
Suprapatellar pouch -0.54 (-1.06, -0.02) -0.48 (-1.00, 0.05) -0.40 (-0.92, 0.13)
Central portion 0.14 (-0.39, 0.67) 0.17 (-0.35, 0.69) 0.27 (-0.25, 0.80)
Posterior femoral recess -0.11 (-1.25, 1.03) -0.16 (-1.29, 0.96) -0.10 (-1.22, 1.02)
Subpopliteal recess -0.58 (-1.28, 0.12) -0.44 (-1.14, 0.26) -0.37 (-1.07, 0.32)
Dependent variable: baseline and change in cartilage volume (ml). Independent variable: knee effusion-synovitis (per 
grade).  
*Adjusted for baseline age, gender, BMI and radiographic osteoarthritis. **Further adjusted for baseline tibial bone
area, bone marrow lesions and cartilage volume (for longitudinal analyses only). #Further adjusted for baseline
cartilage defects. p.a.: per annum.
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5.3.4 Effusion-synovitis and BMLs 
As shown in Table 5.4, in multivariable analyses, effusion-synovitis in most of the 
subregions (except posterior femoral recess) was significantly associated with BMLs at 
baseline, but became non-significant after further adjustment for cartilage defects. 
After 2.6 years follow-up, only suprapatellar pouch effusion-synovitis was 
significantly associated with increases in BMLs after adjustment for age, gender, BMI and 
ROA and baseline BMLs (Table 5.4). Grade-3 effusion-synovitis was significantly associated 
with greater increase in BMLs than grade 1 and 2 effusion-synovitis (Figure 5.1C). The 
significant association disappeared after further adjustment for cartilage defects (Table 5.4).  
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Table 5.4. Associations between knee effusion-synovitis and cartilage volume. 
 Multivariable* Multivariable** Multivariable# 
Baseline bone marrow lesions PR (95%CI)  PR (95%CI) 
Whole knee joint 1.28 (1.13, 1.44) - 1.11 (0.99, 1.25) 
Suprapatellar pouch 1.26 (1.13, 1.41) - 1.07 (0.96, 1.19) 
Central portion 1.19 (1.06, 1.34) - 1.10 (0.98, 1.24) 
Posterior femoral recess 1.04 (0.79, 1.37) - 0.92 (0.71, 1.20) 
Subpopliteal recess 1.24 (1.07, 1.43) - 1.09 (0.96, 1.24) 
Any increase in bone marrow lesions RR (95%CI) RR (95%CI) RR (95%CI) 
Whole knee joint 1.15 (0.94, 1.42) 1.14 (0.92, 1.40) 1.04 (0.85, 1.27) 
Suprapatellar pouch 1.27 (1.04, 1.55) 1.23 (1.01, 1.51) 1.10 (0.90, 1.36) 
Central portion 1.13 (0.92, 1.39) 1.13 (0.91, 1.39) 1.06 (0.87, 1.30) 
Posterior femoral recess 1.10 (0.69, 1.74) 1.08 (0.69, 1.71) 1.01 (0.65, 1.58) 
Subpopliteal recess 1.15 (0.88, 1.50) 1.12 (0.86, 1.47) 1.09 (0.84, 1.42) 
Dependent variable: baseline and increases in bone marrow lesions (yes or no). Independent variable: knee 
effusion-synovitis (per grade).  
*Adjusted for age, gender, BMI, radiographic osteoarthritis and **baseline bone marrow lesions (for longitudinal 
analyses only). # Further adjusted for baseline cartilage defects.  
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5.3.5 Radiographic changes 
Radiographic changes including JSN and osteophytes were assessed cross-sectionally. 
Effusion-synovitis in whole joint (PR: 1.36, 95% CI: 1.12, 1.66), suprapatellar pouch (PR: 
1.44, 95% CI: 1.20, 1.71), posterior femoral recess (PR: 1.51, 95% CI: 1.04, 2.18) and 
subpopliteal recess (PR: 1.37, 95% CI: 1.11, 1.69) was significantly associated with greater 
moderate-severe JSN in multivariable analyses. Effusion-synovitis in whole joint (PR: 1.58, 
95% CI: 1.07, 2.35), suprapatellar pouch (PR: 1.97, 95% CI: 1.38, 2.81), and subpopliteal 
recess (PR: 1.53, 95% CI: 1.00, 2.34) was also significantly associated with osteophytes in 
multivariable analyses. All these significant associations disappeared after adjustment for 
cartilage defects, but remained largely unchanged after adjustment for BMLs. 
5.3.6 Other analyses 
Neither in gender nor ROA subgroup analyses, no significant differences were found 
in terms of the associations between effusion-synovitis and changes in cartilage volume, 
increases in cartilage defects and BMLs. Furthermore, the associations remained largely 
unchanged if the dichotomised effusion-synovitis scores were used as the independent 
variable. 
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5.4 Discussion 
To the best of our knowledge, this is the first study to report the associations between 
subregional effusion-synovitis and multiple knee structural changes in older adults. Knee 
joint effusion-synovitis was associated cross-sectionally with increased knee cartilage 
defects, BMLs, and reduced cartilage volume; and longitudinally, with increases in knee 
cartilage defects and BMLs, and a loss of cartilage volume. The longitudinal associations 
were observed mainly for the suprapatellar pouch, and, to a lesser extent, the subpopliteal 
recess, but not in posterior femoral recess and central portion. The significant associations 
with cartilage defects were independent of BMLs, but the associations with cartilage volume, 
BMLs and radiographic changes were largely mediated by cartilage defects. A dose-response 
association was observed between suprapatellar pouch effusion-synovitis and cartilage 
defects. Our results suggest that knee joint effusion-synovitis, particularly in suprapatellar 
pouch, is causally related to knee cartilage defects and this then leads to BMLs and cartilage 
loss over time in older adults. 
Previous assessment for effusion-synovitis was usually limited to the suprapatellar 
pouch, but an anatomical atlas describes some relatively isolated synovial regions that lie 
within the knee joint cavity (53, 193). In patients with traumatic injuries, 99% effusions were 
found in the central portion, 76% knees in the suprapatellar pouch with only 9% in the 
posterior femoral recess and 2% in subpopliteal recess (60). Using contrast-enhanced MRI, 
Roemer et al. reported that the most common sites for definite synovitis (≥2) were posterior 
to the posterior cruciate ligament (PCL, 71.2%) and the suprapatellar region (59.5%) (111). 
These were consistent with our findings that the prevalence of knee joint effusion-synovitis 
(≥2) was higher in the suprapatellar pouch and central portion, and lower in the posterior 
femoral recess and subpopliteal recess. These regional separations allowed us to examine the 
anatomical distribution patterns of synovial inflammation within the joint cavity, in order to 
investigate whether synovial inflammation in different anatomical subregions has different 
effects on intra-articular pathology. 
So far, there are a few studies that have evaluated the roles of knee effusion and/or 
synovitis in knee osteoarthritic changes, and the findings were inconsistent. Hill et al. utilized 
fat-suppressed spin-echo proton density and T2-weighted MRI to assess synovitis and 
reported that change in synovitis was associated with change in knee pain, but not with focal 
cartilage loss in patients with symptomatic OA (76). Loeuille et al. reported that synovial 
thickening grade detected by contrast-enhanced T1-weighted MRI was associated with 
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cartilage lesion (assessed by arthroscopy) only in the medial tibiofemoral compartment, not 
in the lateral tibiofemoral and patellofemoral compartments (109). In a 30-month cohort 
study, Roemer et al. assessed synovitis or effusion using fat-suppressed fast spin-echo 
intermediate-weighted MRI at baseline and found that synovitis or effusion might increase 
the risk of fast focal cartilage loss in 347 individuals who had or were at higher risk for knee 
OA, but the result was only of statistically borderline significance (p=0.07) (209). This group 
further examined the associations between effusion-synovitis and focal cartilage loss in 514 
subjects with neither cartilage damage nor tibiofemoral ROA. Over 30 months follow-up, 
they found that effusion-synovitis was associated with an increased risk for focal cartilage 
loss in tibiofemoral compartment but not in the patellofemoral compartment (92). Most 
recently, a cross-sectional association of whole knee (across 11 sites) synovitis assessed by 
contrast-enhanced MRI with widespread cartilage damage was found in the same study (210). 
These studies did not assess diffuse cartilage volume loss using quantitative MRI 
measurement, mostly assessed synovitis/effusion around suprapatellar area, and did not 
examine other structural changes such as BMLs.  
Using fat suppressed T2-weighted fast spin echo MRI, we found that joint effusion-
synovitis in suprapatellar pouch was consistently associated with focal (as assessed by 
cartilage defects) and diffuse (as assessed by reduced cartilage volume) cartilage loss in older 
adults in both cross-sectional and longitudinal analyses, indicating that suprapatellar pouch 
effusion-synovitis could induce focal cartilage loss observed largely at an earlier stage as well 
as diffuse cartilage loss seen mainly at a later stage of OA. The associations with cartilage 
volume loss decreased in magnitude by 17% after further adjustment for cartilage defects and 
by 7% after adjustment for BMLs suggesting that effects of effusion on cartilage volume loss 
are largely through cartilage defects. 
Additionally, our study explored the effects of effusion-synovitis in other subregions. 
We found that effusion-synovitis in subpopliteal recess was cross-sectionally and 
longitudinally associated with increased cartilage defects, but its association with cartilage 
volume loss was not significant. These indicated that subpopliteal recess effusion-synovitis 
might only cause focal cartilage loss. Furthermore, although effusion-synovitis in the central 
portion and posterior femoral recess was cross-sectionally associated with increased cartilage 
defects, no longitudinal associations with cartilage defects and cartilage volume were found, 
suggesting that effusion-synovitis in these 2 subregions might not play a significant role in 
inducing cartilage loss. 
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The pivotal role that subchondral BMLs play in knee pain and disease progression in 
knee OA has been reported (183, 211), but the causes of the marrow signal changes are still 
uncertain. Hypothetically, synovial fluid can be forced under pressure into subchondral bone 
marrow through defects in cartilage or bone, increasing marrow fluid and eventual trabecular 
bone excavation, and thus cause BMLs, which is similar to the mechanism of cyst formation 
(184). Yet very little clinical evidence has emerged about the relationship between effusion-
synovitis and subchondral BMLs. There is only one cross-sectional study reporting that 
quantitative synovial membrane volume measured in T1-weighted contrast-enhanced MRI 
was significantly associated with the volume of subchondral BMLs (120), but no cohort 
studies have reported this association so far. Our study confirmed the significant cross-
sectional associations between effusion-synovitis in most joint regions and BMLs, and was 
the first to report that longitudinal association between suprapatellar pouch effusion-synovitis 
and increases in BMLs over time. The significant cross-sectional and longitudinal 
associations disappeared after further adjustment for cartilage defects, indicating that joint 
effusion may lead to BMLs via cartilage defects. This would be consistent with our previous 
study where defects predicted BML worsening (212). 
This study reported the most consistent associations between suprapatellar pouch 
effusion-synovitis and cartilage defects, cartilage volume loss and BML, suggesting this may 
be the most important site or the most easily detected (197). The volume necessary was large 
(but common in our unselected sample) as the associations were confined to grade 2 or above 
effusions. Effusion-synovitis in subpopliteal recess may also cause focal cartilage loss. 
Although effusion-synovitis in major subregions was associated with JSN and osteophytes, 
causal relationships are unclear due to the cross-sectional nature of these findings.  
The strengths of the present study lie in the comprehensive MRI and radiographic 
measurements and the effort taken to untangle site specific and structural associations. There 
are several potential limitations in our study. First, we had knee MRI scans in 977 subjects at 
baseline, and only 404 subjects at follow-up owing to decommissioning of the MRI scanner; 
however, there were no differences in demographic factors between those who remained in 
the study and who dropped out. Second, we did not have radiographic assessments at follow-
up, because x-ray is insensitive to detect the changes over this short period, so we were not 
able to examine the associations between effusion-synovitis and changes in radiographic 
changes in this study. Lastly, measurement error may influence results. However, all 
measures were highly reproducible suggesting this is unlikely. 
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There are dose-dependent and independent associations between knee joint effusion-synovitis 
and knee cartilage defects in both cross-sectional and longitudinal analyses, suggesting a 
potential causal relationship. The associations of effusion-synovitis with BMLs and cartilage 
volume were largely dependent on cartilage defects suggesting potential causal pathways. 
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6.1  Introduction 
OA contributes greatly to overall disability in our aging society. Accumulating 
evidence shows that OA is not a degenerative disease but involves dynamic biological and 
inflammatory processes (213). Synovial inflammation, which is directly responsible for 
clinical symptoms, is a feature of early and advanced knee OA (51, 214). Low-grade synovial 
inflammation may contribute to the progression of chondropathy and the deterioration of 
other joint structures by producing a number of pro-inflammatory mediators (206, 207). 
Additionally, the histological changes in synovial tissue are heterogeneous at different 
locations of the affected joint (109). It is unclear whether synovial morphological changes are 
the origin or consequence of joint structural abnormalities in OA (215). Biologically, it is 
suggested that synovial inflammation was induced by debris from cartilage breakdown (216). 
However, increasing evidence suggests that synovial abnormalities can precede joint 
pathological changes, especially cartilage loss (92, 209, 217). We recently reported that 
effusion-synovitis (a MRI feature reflecting synovial inflammation) was independently 
associated with knee cartilage defects cross-sectionally and longitudinally, suggesting a 
possible causal relationship (94). The natural history of MRI-detected effusion-synovitis in 
older people has not been reported so far. It is unknown if knee structural abnormalities 
including cartilage defects, reduced cartilage volume, bone marrow lesions (BMLs) and 
meniscal lesions can predict effusion-synovitis. 
Joint effusion can be visually distinguished from synovitis using contrast-enhanced 
(CE) MRI after intravenous gadolinium injection, but this assessment is not commonly used 
for research because of potential side effects and high cost. Recently, the term “effusion-
synovitis” has been proposed for effusion and synovitis because these two features cannot be 
differentiated by non-CE MRI (115). We assessed regional effusion-synovitis using a semi-
quantitative scoring system in four compartments of the knee: suprapatellar pouch, central 
portion, posterior inter-condylar recess and subpopliteal recess, and found that regional 
effusion-synovitis scores were well correlated with osteoarthritic features (79, 94). However, 
a quantitative measurement of effusion-synovitis has not been established. 
The aims of this study were, therefore, to describe the natural history of effusion-
synovitis using a quantitative measure in a population-based sample, and to investigate the 
longitudinal associations between effusion-synovitis and knee structural factors including 
cartilage defects, cartilage volume, subchondral BMLs and meniscal pathology over 2.7 years 
in older adults. 
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6.2  Materials and Methods  
6.2.1 Characteristics of participants 
This study used subjects from the TASOAC study as described in section 3.2. 
 
6.2.2 Knee MRI sequences 
T1 and T2 weighted fat saturated MRIs sequences as described in section 3.2.3. 
 
6.2.3 Knee MRI measurements 
6.2.3.1 Effusion-synovitis 
Baseline and follow-up semi-quantitative effusion-synovitis was scored in four 
subregions as described in section 3.2.3.1 and displayed in Figure 3.2. Quantitative effusion-
synovitis area was measured in the whole joint at baseline and follow-up as described in 
section 3.2.3.1  and displayed in Figure 3.3. 
 
6.2.3.2 Cartilage volume 
Baseline and follow-up total cartilage volume was measured on MRI as described in 
section 3.2.3.4 . 
 
6.2.3.3 Cartilage defects  
Baseline and follow-up cartilage defects were assessed from 0-4 on MRI as described 
in section 3.2.3.3 . 
 
6.2.3.4 BMLs 
Baseline and follow-up BMLs were assessed on MRI as described in section 3.2.3.2 . 
 
6.2.3.5 Meniscal pathology 
Baseline and follow-up meniscal pathology was assessed on MRI as described in 
section 3.2.3.5 . 
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6.2.3.6 Tibial bone area 
Baseline and follow-up tibial bone area was measured on MRI as described in section 
3.2.3.6 . 
 
6.2.4 Knee pain 
Knee pain was assessed using the WOMAC scoring system as described in section 
3.2.2.  
 
6.2.5 Knee X-ray 
Knee radiographs were taken and scored for ROA as described in section 3.2.4. 
 
6.2.6 Anthropometrics 
Height, weight and BMI was measured as previous described in section 3.2.1. 
 
6.2.7 Statistical analysis 
Comparisons of baseline characteristics among groups with increased, stable and 
decreased effusion-synovitis were carried out using one-way ANOVA. The statistically 
significant differences between subjects who completed the study and who were lost to 
follow-up were evaluated using t-test or chi-square tests (as appropriate). Univariable and 
multivariable linear regressions were used to assess the associations between effusion-
synovitis and structural abnormalities at baseline, between baseline effusion-synovitis and 
changes in structural abnormalities, or between baseline structural abnormalities and change 
in effusion-synovitis, before and after adjustment for age, gender, BMI, tibial bone area 
and/or ROA.  
Standard diagnostic checks of model fit and residuals were routinely performed, and 
data points with large residuals and/or high influence were investigated for data errors. 
Interactions between ROA and exposure factors on changes in outcomes were investigated by 
testing the statistical significance of the coefficient of a product term (an exposure × ROA) 
after adjustment for confounders.  
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6.3  Results  
6.3.1 Characteristics of participants 
A total of 1,100 subjects (51% female) aged between 50 and 80 years (mean 63 years) 
participated in the TASOAC study. More than half participants did not have MRI at follow-
up because local MRI machine was decommissioned and became unavailable for research 
purposes. There were 63 participants (age: 64±7; female sex: 56%; BMI: 27.8±5.6 kg/m2) 
who were lost to follow-up before the MRI machine was decommissioned. There were no 
significant differences in baseline characteristics between these subjects and those who 
completed follow-up MRIs (all p>0.05). The current study consisted of a sample of 406 
subjects (age: 63±7 years; female sex: 50%; BMI: 27.7±4.5 kg/m2; and ROA: 57%) who had 
MRI measures at baseline and 2.7 years later. Prevalence of JSN and osteophytes in these 
subjects was 56% (grade 1: 41%, grade 2: 12% and grade 3: 3%) and 8% (grade 1: 5%, grade 
2: 2% and grade 3: 1%), respectively. There were no significant differences in baseline 
demographics, cartilage defects, BMLs and cartilage volume between the subjects who were 
included in the current study and the rest of the cohort (data not shown).  
Baseline characteristics of the study sample are shown in Table 6.1. There were no 
significant differences in female sex, BMI, knee pain, cartilage defects, BMLs and meniscal 
lesions and ROA among those with increased, stable and decreased effusion-synovitis. Those 
with stable effusion-synovitis were younger, and those with decreased effusion-synovitis had 
higher baseline maximal area of effusion-synovitis. 
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Table 6.1. Characteristics of participants at baseline. 
  Knee effusion-synovitis   
Characteristics Decrease Stable Increase P value 
 (n=88) (n=201)  (n=117)  
Age (year) 63.6 (7.1) 61.7 (6.7) 63.5 (7.9) 0.03 
Female (%) 45 54 46 0.28 
BMI (kg/m2) 27.5 (4.6) 27.8 (4.0) 27.4 (5.0) 0.65 
WOMAC knee pain score (0-45) 3.3 (5.4) 3.4 (6.7) 3.7 (6.8) 0.87 
WOMAC knee pain present (%) 55% 46% 50% 0.51 
Cartilage volume (ml) 8.5 (1.8) 8.4 (1.9) 8.5 (2.0) 0.78 
Cartilage defect (%) 56 45 47 0.22 
Bone marrow lesion (%) 38 36 33 0.78 
Meniscal lesion (%) 93 84 86 0.12 
Effusion-synovitis (cm2) 2.9 (1.7) 1.2 (0.9) 1.4 (1.0) <0.01 
Knee ROA (%) 56 54 63 0.27 
Values expressed as mean (standard deviation) unless percentages. 
 Χ2 test was used for the comparisons.  
BMI, body mass index; WOMAC, western Ontario and McMaster universities; ROA, radiographic 
osteoarthritis.  
Bold p value indicates statistically significant difference at α=0.05. 
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6.3.2 Natural history of effusion-synovitis 
At baseline, the mean (±SD) size of effusion-synovitis was 1.64 cm2 (±1.34 cm2), 
ranging from 0.04 cm2 to 8.91 cm2. Male subjects had larger baseline and follow-up effusion-
synovitis size compared to females (Table 6.2). Over 2.7 years follow-up, the mean size of 
effusion-synovitis changed to 1.75 cm2 (±1.29 cm2), with 29% (N=88) increasing in size, 
50% (N=201) remaining stable and 22% (N=117) decreasing in size in total sample (Table 
6.2). In males, 31% increased in size, 46% remained stable and 23% decreased in size of 
effusion-synovitis. In comparison, 27% increased in size, 53% remained stable and 20% 
decreased in size of effusion-synovitis in females (Table 6.2). 
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Table 6.2. Natural history of knee effusion-synovitis in total sample and gender 
subgroups. 
Effusion-synovitis 
area Total sample Male Female   
  Mean (95% CI) Mean (95% CI) Mean (95% CI) P value 
Baseline (cm2) 1.64 (1.51, 1.76) 1.78 (1.59, 1.96) 1.49 (1.31, 1.67) <0.01 
Follow-up (cm2) 1.75 (1.62, 1.87) 1.92 (1.73, 2.11) 1.57 (1.41, 1.74) <0.01 
 Percentage (95% CI) Percentage (95% CI) Percentage (95% CI)   
Decrease (%) 21.67 (17.92, 25.97) 23.53 (18.18, 29.87) 19.80 (14.85, 25.91) 0.67 
Stable (%) 49.51 (44.64, 54.38) 45.59 (38.84, 52.50) 53.47 (46.53, 60.27) 0.26 
Increase (%) 28.82 (24.60, 33.44) 30.88 (24.89, 37.59) 26.73 (21.06, 33.29) 0.62 
 T-test and Χ2 test was used for the comparisons.  
Bold p value indicates statistically significant difference between males and females at α=0.05. 
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6.3.3 Associations between effusion-synovitis and knee structures 
Cross-sectionally, effusion-synovitis maximal area was significantly and positively 
associated with cartilage defects and BMLs, and negatively with cartilage volume, after 
adjustment for age, gender, BMI, tibial bone area and/or ROA (Table 6.3). No significant 
associations were found between effusion-synovitis and meniscal lesions at baseline.  
Baseline effusion-synovitis maximal area was significantly and positively associated 
with changes in knee cartilage defects and BMLs over 2.7 years, and negatively with change 
in knee cartilage volume in multivariable analyses (Table 6.4). No significant association was 
found between baseline effusion-synovitis area and change in meniscal lesions.  
In contrast, baseline structural measures were not significantly associated with change 
in effusion-synovitis maximal area (Table 6.5) or an increase in effusion-synovitis area 
defined using LSC (Table 6.6). 
There were no significant interactions between effusion-synovitis maximal area and 
ROA on changes in other joint structures, or between other joint structures and/or ROA on 
change in effusion-synovitis maximal area (data not shown), so subjects with and without 
ROA were combined for analyses. 
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Table 6.3. Associations between baseline knee structural factors and baseline effusion-
synovitis. 
  
Baseline effusion-synovitis area 
Univariable β (95% CI) Multivariable* β (95% CI) 
Baseline structural factors    
Cartilage defect  0.21 (0.16, 0.26) 0.15 (0.10, 0.21) 
Cartilage volume 0.02 (-0.05, 0.08) -0.18 (-0.28, -0.07) 
Bone marrow lesion 0.14 (0.04, 0.25) 0.10 (0.00, 0.19) 
Meniscal lesion 0.11 (0.01, 0.22) 0.06 (-0.04, 0.16) 
Independent variable: baseline structural factors (score or cartilage volume) 
Dependent variable: baseline effusion-synovitis area (continuous variable) 
*Adjusted for age, gender, body mass index, tibial bone area and radiographic osteoarthritis. 
Bold p value indicates statistically significant difference at α=0.05. 
 
  
Chapter 6: Quantitative knee effusion-synovitis and knee structural abnormalities  
 
 104 
Table 6.4. Associations between baseline knee effusion-synovitis and change in structural 
factors. 
  
Baseline effusion-synovitis area 
Univariable β (95% CI) Multivariable* β (95% CI) 
Change in structural factors    
Cartilage defect  0.18 (0.09, 0.27) 0.18 (0.07, 0.29) 
Cartilage volume -0.47 (-0.74, -0.21) -0.40 (-0.71, -0.09) 
Bone marrow lesion 0.23 (0.12, 0.35) 0.17 (0.05, 0.30) 
Meniscal lesion -0.05 (-0.14, 0.05) -0.02 (-0.13, 0.09) 
Independent variable: baseline effusion-synovitis area (continuous variable) 
Dependent variable: change in structural factors (score or cartilage volume) 
*Adjusted for age, gender, body mass index, tibial bone area and radiographic osteoarthritis. 
Bold p value indicates statistically significant difference at α=0.05. 
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Table 6.5. Associations between baseline knee effusion-synovitis and change in structural 
factors. 
  Change in effusion-synovitis area 
  Univariable β (95% CI) Multivariable* β (95% CI) 
Baseline structural factors    
Cartilage defect  -0.04 (-0.09, 0.00) -0.02 (-0.08, 0.03) 
Cartilage volume 0.00 (-0.06, 0.06) -0.01 (-0.11, 0.09) 
Bone marrow lesion -0.04 (-0.13, 0.05) -0.04 (-0.13, 0.05) 
Meniscal lesion -0.04 (-0.13, 0.05) -0.03 (-0.13, 0.06) 
Independent variable: baseline structural factors (score or cartilage volume) 
Dependent variable: change of effusion-synovitis area (continuous variable) 
*Adjusted for age, gender, body mass index, tibial bone area and radiographic osteoarthritis. 
Bold p value indicates statistically significant difference at α=0.05. 
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Table 6.6. Associations between knee structural factors and effusion-synovitis. 
  Effusion-synovitis   
 Model A Model B 
  Multivariable* OR (95% CI) Multivariable* OR (95% CI) 
Structural factors     
Cartilage defect  0.92 (0.58, 1.47) 1.32 (1.07, 1.64) 
Bone marrow lesion 0.87 (0.54, 1.39) 1.27 (1.06, 1.53) 
Meniscal lesion 0.85 (0.42, 1.71) 0.99 (0.78, 1.27) 
Model A: 
Independent variable: baseline scores of structural factors  
Dependent variable: increase in effusion-synovitis (increase vs. no increase) 
Model B: 
Independent variable: baseline effusion-synovitis area 
Dependent variable: change in structural factors (increase vs. no increase) 
*Adjusted for age, gender, BMI, tibial bone area and ROA. 
BMI, body mass index; ROA, radiographic osteoarthritis. 
Bold p value indicates statistically significant difference at α=0.05. 
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6.4  Discussion 
This longitudinal study investigated the natural history and clinical significance of 
effusion-synovitis in a randomly selected older cohort. We assessed effusion-synovitis by 
measuring the maximal area, and found that the proportions of worsening (29%) or 
improving (22%) effusion-synovitis were similar, with 49% remaining stable. Baseline 
effusion-synovitis was associated with changes in cartilage measures and subchondral BMLs, 
but baseline cartilage measures and BMLs were not associated with change in effusion-
synovitis. This suggests a potential causal pathway from effusion-synovitis to cartilage and 
bone abnormalities, but not vice versa, in older adults. 
This study was the first study to report the natural history of effusion-synovitis in a 
community-based cohort. Previous studies mainly investigated the prevalence of synovial 
inflammation in asymptomatic or OA cohorts, which were not generalizable to the older 
population. Besides, the prevalence of synovial inflammation has ranged from 10% to 80% at 
different sites according to different definitions (92, 108, 111, 113, 218, 219). The conflicting 
data may be due to variations in assessment techniques, grading systems, populations and 
study designs. To our knowledge, the information for incidence or progression of synovial 
inflammation in OA was very limited. Hill et al. reported that about 15% to 20% of the knee 
synovitis score improved and 20% worsened at 30-month follow-up in symptomatic OA 
patients (76). In our study, the increase (incidence and progression) in effusion-synovitis was 
observed in nearly one third of the participants, and the decrease was seen in 22% of the 
participants.  
Unlike the previous scoring system, we assessed effusion-synovitis by measuring its 
maximal area. 2-D sagittal T2-weighted images with an inter-slice gap of 0.5 to 1.0 mm did 
not allow measuring the real volume of joint effusion-synovitis. Joint effusion-synovitis can 
be dynamic, and this is why maximal effusion-synovitis areas at baseline and follow-up were 
observed on slightly different slices (Figure 1C and 1D); however, maximal effusion-
synovitis area measurement is simple and reproducible, and has construct and predictive 
validities. Furthermore, the maximal area was highly correlated with the proxy volume and 
the semi-quantitative scores of effusion-synovitis. This suggests that this maximal effusion-
synovitis area measurement has concurrent validity. The external validity was further tested 
in another study (Vitamin D Effect on Osteoarthritis Study), in which MRI images had no 
inter-slice gaps. It showed a very high correlation (r=0.97) between 2D- maximal area and 
3D- volume of effusion-synovitis. The proxy volume of effusion-synovitis in our sample 
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(mean±SD: 4.7±2.8 ml) underestimated the real volume measured in other studies [17.7±7.0 
ml (220) and 25.5±22.3 ml (190)]. Therefore, we did not use the proxy volume as the 
outcome in this study. Furthermore, we calculated the variations of effusion-synovitis from 
baseline to follow-up using the LSC (170). This may minimalize the measurement errors and 
offer a more reasonable tool to describe the natural history of effusion-synovitis. 
Our findings confirmed that synovial inflammation could be a precursor of OA, which 
was consistent with our recent findings that effusion-synovitis score assessed using semi-
quantitative measurements was associated with increased incidence/progression of cartilage 
degradation and BMLs (94). Synovial inflammation has been shown to be predictive of OA 
outcomes such as radiographic changes and total knee replacement (91, 93), and was 
independently linked to knee symptoms (83, 85). Although we found that cartilage defects 
and BMLs were associated with effusion-synovitis cross-sectionally, we did not find 
significant associations between baseline cartilage, bone and meniscal measures and change 
in effusion-synovitis. Hypothetically, structural degradation products such as cartilage 
fragments could irritate synovial membrane and trigger the pro-inflammatory processes 
within the joint capsule (216), but this may  happen in a subset of OA, e.g., those with post-
traumatic or injury-related phenotypes, or in late-stage OA. Our current findings indicate that 
in a community-based older population, the inflammatory phenotype of OA was prevalent, 
and inflammation may initiate early osteoarthritic changes. Furthermore, considering its 
potential ability to regress or resolve, effusion-synovitis can be a promising therapeutic target 
for slowing the disease progression of knee OA. 
The strength of this study is that we studied a community-based population with a 
large sample size using a quantitative measurement to assess change in effusion-synovitis 
size over time. It also has several potential limitations. First, loss of follow-up MR images 
was caused by unavailability of local MRI machine for research purposes. Assuredly there 
were no significant differences in demographic characteristics between included participants 
and those who lost to follow-up. Second, we used non-CE MRI, which was unable to 
differentiate synovial fluid and synovial thickening, so measurement of effusion-synovitis 
may not actually reflect synovitis status. Third, we did not assess synovitis at other sites (e.g. 
Hoffa’s fat pad) that may be associated with osteoarthritic changes; however, effusion-
synovitis is a potentially better marker of synovial activation than Hoffa’s synovitis (92). 
Lastly, we did not evaluate the re-scan reproducibility for the MR images, which would 
potentially influence the quantified area measurement that goes beyond the field of view. 
Chapter 6: Quantitative knee effusion-synovitis and knee structural abnormalities  
 
 109 
In conclusion, knee joint effusion-synovitis was not static in older adults. It was 
predictive of, but not predicted by, other structural abnormalities suggesting a potential role 
in knee early osteoarthritic changes. 
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8.1  Introduction 
Osteoarthritis (OA) was generally thought of as a ‘non-inflammatory’ type of 
arthritis; however, localised low-grade inflammation is now known to be an important factor 
in OA pathogenesis (103, 208, 222). The development of chronic inflammation in OA 
following joint injury or metabolic dysfunction may contribute to the formation of a cycle of 
local tissue lesions, inflammation and repair (224). Notably, synovial activation (effusion 
and/or synovitis) has been considered as a precursor of OA outcomes such as radiographic 
changes and total knee replacement (91, 93). It is independently associated with clinical 
symptoms, such as knee pain and physical function (83, 85). Studies have demonstrated the 
link between synovial inflammation and structural changes of knee OA (51, 92, 97, 110), 
suggesting that reducing synovial inflammation may be a potential avenue for slowing 
disease progression in knee OA. This is extremely important, as there are no proven treatment 
options to modify disease progression in OA so far.  
Importantly, comparing to articular and bony alterations, synovial inflammation has a 
greater potential to regress or resolve (225) which creates a treatment opportunity. Previous 
pharmaceutical managements such as non-steroidal anti-inflammatory drugs (NSAIDs) and 
intra-articular steroid injection have been recommended for OA patients particularly those 
with joint effusion (234); however, use of these can result in side-effects and drug 
intolerance, especially during long-term use (235, 236) . It is therefore important to identify 
safer and more cost-effective interventions targeting synovial inflammation in OA (237). 
In observational studies vitamin D deficiency has been associated with cartilage loss 
and pain (150, 153). In animal models, vitamin D supplementation has a protective effect in 
OA by reducing the expression of pro-inflammatory cytokines (238). Furthermore, an 
exercise-interventional study has found that vitamin D sufficiency increases anti-
inflammatory cytokines response to muscular injury (239). So far, RCT evidence on the 
efficacy of vitamin D supplementation for knee OA is limited and inconsistent. While one 
study suggested it had beneficial effects on symptoms (154), another showed no effects on 
symptoms and cartilage loss (155). In our recent Vitamin D Effect on Osteoarthritis (VIDEO) 
study in patients with knee OA and low serum vitamin D levels vitamin D supplementation 
over 24 months had no significant effect on knee pain or cartilage morphology but might 
have modest effects on knee function loss and bone marrow lesions (240). However, none of 
these studies has investigated the effects of vitamin D on synovial inflammation. We 
hypothesised that vitamin D may reduce synovial inflammation in patients with knee OA. 
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The aim of this post-hoc analysis was, therefore, to examine the effect of vitamin D 
supplementation over 24 months on effusion-synovitis (a MRI marker of synovial 
inflammation) in the VIDEO study. 
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8.2  Materials and Methods  
8.2.1 Trial design 
This study is a post-hoc analysis of the original VIDEO study which has been 
described in section 3.3. 
 
8.2.2 Participants 
This chapter used participants from the VIDEO study as described in section 3.3. 
  
8.2.3 Interventions 
Participants in the intervention group were given a monthly capsule of 50,000 IU 
(1.25 mg) vitamin D3 (cholecalciferol) for 24 months (178) as described in section 3.3.1. 
 
8.2.4 Outcomes 
The co-primary efficacy endpoint measures of the originally specified trial were MRI 
assessment of knee cartilage volume changes from baseline to month 24, as well as the 
WOMAC) score (165). Volume and score of knee effusion-synovitis were used as outcomes 
in this post-hoc analysis. 
 
8.2.4.1 Knee MRI sequences 
The MRI sequences used in this study have been described in section 3.3.7. 
 
8.2.4.2 Knee MRI measurements of effusion-synovitis 
Quantitative measurement 
Quantitative effusion-synovitis volume was measured at baseline and follow-up as 
described in section 3.2.3.1 and displayed in Figure 3.4. 
Semi-quantitative measurement 
Effusion-synovitis score was assessed at baseline and follow-up as described in 
section 3.2.3.1 and displayed in Figure 3.2. 
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8.2.5 Randomisation 
Participants were allocated to either vitamin D or placebo arm at a ratio of 1:1 based 
on computer-generated random numbers as described in section 3.3.2. 
 
8.2.6 Blinding 
As described in section 3.3.3, participants, research coordinators and investigators 
were all blinded to treatment assignment. 
 
8.2.7 Trial monitoring and safety assessment 
The project manager visited and monitored each site to examine trial procedures, 
which was previously described in section 3.3.4. 
 
8.2.8 Sample size calculation 
Sample size calculation has been described in section 3.3.11. 
 
8.2.9 Statistical analysis 
Baseline characteristics were compared between two groups with the use of Student’s t-tests 
or Chi-square tests. Independent t-tests were used to compare changes in effusion-synovitis 
volume from baseline to follow-up between groups. In secondary analyses, the minimal 
clinically important difference (MCID) was estimated for effusion-synovitis volume (both the 
absolute and the relative annul change). A reduction of mean WOMAC function score ≥ 7 
was used as an anchor to determine the cut-off of effusion-synovitis volume in patients who 
actually experienced clinically significant improvement (167). A least significant change 
(LSC) criterion was used to define an increase, stable or a decrease in effusion-synovitis 
volume. This takes into account measurement error and the correlation between the baseline 
and follow-up measurements (170). The formula was as follows: !"# = 1.96×* 2 1 − -  
(σ = the standard error of the mean; ρ = the serial correlation). For example, LSC of total 
effusion-synovitis volume was calculated to be 1.81 ml (where σ = 1.17 and ρ = 0.69) in this 
study. Therefore, participants were categorised as having an increase in effusion-synovitis 
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volume if change in effusion-synovitis volume was   +1.81 ml, having a decrease if  
change in  effusion-synovitis was  -1.81 ml, and having a stable effusion-synovitis if 
change in effusion-synovitis volume was between -1.81 and +1.81 ml. Logistic regression 
was applied to examine the effects of intervention when dichotomised outcomes of effusion-
synovitis (improvement versus no improvement; increase versus no increase, or decrease 
versus no decrease) were used as described in section 3.2.3.1 . 
For intention-to-treat analysis, multiple imputations were used to address missing data 
due to loss to follow-up and non-response. Imputations were performed separately for each 
treatment group and each outcome, using baseline values, age, gender, BMI and serum 25-
(OH)D level. All the data analysis was performed on Stata V13.0 (Stata Corp., College 
Station, Texas, USA). A two-sided p value of 0.05 was considered statistically significant. 
 
8.3 Results  
8.3.1 Characteristics of participants 
The flowchart of participants through the study is described in Figure 3.5. Of 599 
participants were screened for eligibility, 413 subjects were randomly assigned to either 
vitamin D or placebo group. Over 24 months, 28 (13.4%) in the vitamin D group and 45 
(22.1%) in the placebo group withdrew from the study. Three hundred and forty patients 
(82.3%) completed the follow-up. The number of patients who discontinued treatment 
allocation was larger in the placebo group than the vitamin D group (21 versus 8). The major 
reason for discontinuation was non-adherence to the protocol when low 25-(OH)D levels 
were disclosed to the participants by their general practitioners. Intention-to-treat analyses 
were performed in all 413 randomized participants. The mean age of participants was 63.2 ± 
7.0 years, with 208 (50%) females and a mean BMI of 29.6 ± 5.0 kg/m2. Using a semi-
quantitative grading assessment, baseline prevalence of effusion-synovitis (score ≥ 2) was 
47.7%, which were similar in two groups (48.5% in vitamin D versus 46.8% in placebo). 
Participants’ characteristics at baseline were comparable between two groups (Table 8.1). 
Other characteristics of the participant at baseline were comparable between two groups 
(Table 8.1) (240). 
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Table 8.1. Participant characteristics at baseline. 
Total Sample Vitamin D (N = 209) Placebo (N = 204) P value 
Age (y) 63.55 (6.88) 62.85 (7.22) 0.32 
Women (%) 51 50 0.92 
Body mass index (kg/m2) 29.57 (5.39) 29.64 (4.62) 0.88 
Radiographic osteoarthritis (%) 96 96 0.84 
Plasma 25-hydroxyvitamin D (nmol/l) 43.74 (11.80) 43.81 (12.66) 0.95 
Effusion-synovitis volume (ml) 7.93 (7.81) 7.98 (9.20) 0.95 
Effusion-synovitis prevalence (%) 49  47  0.60 
Results are shown as mean (SD) or percentage unless stated otherwise. 
Student t-test or χ2-test was used for the comparison. 
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8.3.2 Outcome 
8.3.2.1 Intention-to-treat analysis 
The serum 25-(OH) D levels increased by an average 40.6 ± 19.5 nmol/l in the 
vitamin D group but only 6.7 ± 17.9 nmol/l in the placebo group throughout the study period. 
This has been described in detail elsewhere (240). In the total study sample, total effusion-
synovitis volume increased from baseline (8.0 ± 8.5 ml) to follow-up (9.0 ± 10.5 ml). The 
mean effusion-synovitis volume increased from 8.0 ± 9.2 ml to 10.0 ± 12.3 ml in the placebo 
group (p=0.08), but remained stable in the vitamin D group (8.0 ± 7.8 ml to 8.0 ± 8.4 ml).  
There were statistically significant differences in absolute and relative effusion-
synovitis volume change between groups (-1.94 ml over 24 months or -45% p.a.) (Table 8.2).  
The statistically significant differences were only evident in patients who had baseline 
effusion-synovitis (score ≥ 2), not in those without baseline effusion-synovitis (Table 8.2). 
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Table 8.2. Two-year changes in total knee effusion-synovitis between vitamin D and placebo groups. 
Effusion-synovitis measures Vitamin D  Placebo  Between Group Difference*   
 Mean (95% CI) Mean (95% CI) Mean (95% CI) P value 
Whole sample N = 209 N = 204   
Volume, absolute change (ml) 0.26 (-0.82, 1.34) 2.20 (1.01, 3.38) -1.94 (-3.54, -0.33) 0.02 
Volume, relative change (p.a.)# 16% (-8%, 39%) 60% (31%, 89%) -45% (-82%, -7%) 0.02 
Grade, absolute change (0-3) 0.04 (-0.06, 0.14) 0.14 (0.03, 0.25) -0.10 (-0.25, 0.05) 0.19 
Those with baseline effusion-synovitis  N = 106 N = 108   
Volume, absolute change (ml) 0.13 (-1.09, 1.35) 2.17 (0.88, 3.46) -2.04 (-3.83, -0.25) 0.03 
Volume, relative change (p.a.)# 9% (-1%, 18%) 28% (17%, 38%) -19% (-33%, -5%) 0.01 
Grade, absolute change (0-3) -0.05 (-0.15, 0.06) 0.07 (-0.04, 0.18) -0.12 (-0.27, 0.04) 0.14 
Those without baseline effusion-synovitis N = 103 N = 96   
Volume, absolute change (ml) 0.80 (-0.22, 1.82) 1.97 (0.64, 3.30) -1.17 (-0.50, 2.85) 0.17 
Volume, relative change (p.a.)# 60% (-144%, 264%) 351% (69%, 632%) -290% (-57%, 638%) 0.10 
Grade, absolute change (0-3) 0.57 (0.30, 0.83) 0.74 (0.40, 1.09) -0.18 (-0.26, 0.62) 0.43 
All analyses compared baseline vs. 2-year outcomes. 
*The results in this table were generated on an imputed dataset. 
#Relative change = (absolute change/baseline value)/time interval.    
Bold p value indicates statistically significant difference at α=0.05.    
CI, confidence interval; p.a., per annum.    
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8.3.2.2 Regional effusion-synovitis analysis 
In subregional analyses, the absolute changes in volume and score of effusion-
synovitis in suprapatellar pouch were less in the vitamin D than the placebo group, and the 
between group differences were statistically significant (Table 8.3). In contrast, there were no 
significant differences between two groups in changes in effusion-synovitis volume and score 
in other joint cavity (Table 8.3).  
Clinical improvements in effusion-synovitis volume (absolute and percentage 
changes) were further defined using MCID. The proportions with improvements in 
percentage changes of total and suprapatellar effusion-synovitis were significantly higher in 
the vitamin D compared to placebo group (Table 8.3 and Table 8.4). In contrast, there were 
no statistically significant differences between groups in the improvements in effusion-
synovitis in other regions of the joint (Table 8.3 and Table 8.4). When effusion-synovitis 
volume was categorised as an increase or a decrease by LSC, the proportions with an increase 
of effusion-synovitis volume in total, suprapatellar or other regions were higher in the 
placebo group, while the proportion with a decrease of suprapatellar effusion-synovitis 
volume was higher in the vitamin D group (Table 8.4). 
Per protocol analysis comparing those reached a 25-(OH)D level over 60 nmol/l at 
month 3 to those who did not (253 versus 146) showed similar results of change in effusion-
synovitis volume (data not shown). 
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Table 8.3. Two-year changes in regional knee effusion-synovitis between vitamin D and placebo groups. 
Effusion-synovitis measures Vitamin D (N = 129) Placebo (N = 132) Between Group Difference*   
  Mean (95% CI) Mean (95% CI) Mean (95% CI) P value 
Suprapatellar pouch     
Volume, absolute change (ml) 0.04 (-1.46, 1.53) 2.53 (0.84, 4.22) -2.49 (-4.74, -0.25) 0.03 
Volume, relative change (p.a.)# 19% (-111%, 149%) 148% (-6%, 302%) -129% (-330%, 72%) 0.21 
Grade, absolute change (0-3) -0.02 (-0.14, 0.11) 0.18 (0.05, 0.31) -0.20 (-0.38, -0.02) 0.03 
Other cavity     
Volume, absolute change (ml) 0.12 (-0.13, 0.38) 0.40 (0.13, 0.67) -0.28 (-0.65, 0.09) 0.14 
Volume, relative change (p.a.)# 10% (-15%, 34%) 39% (11%, 68%) -30% (-67%, 8%) 0.12 
Grade, absolute change (0-3) 0.04 (-0.07, 0.16) 0.15 (0.03, 0.28) -0.11 (-0.28, 0.06) 0.21 
All analyses compared baseline vs. 2-year outcomes.       
*The results in this table were generated on an imputed dataset.    
#Relative change = (absolute change/baseline value)/time interval.    
Bold p value indicates statistically significant difference at α=0.05.    
CI, confidence interval; p.a., per annum.    
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Table 8.4. Changes in knee effusion-synovitis exceeding MCID or LSC over two years. 
Effusion-synovitis measures Vitamin D Placebo 
RR of achieving difference in 
vitamin D compared to placebo 
group* 
 
 Percentage (N) Percentage (N) RR (95% CI) P value 
Whole joint     
Improvement in absolute change by MCID  53% (96) 44% (76) 1.22 (0.98, 1.52) 0.07 
Improvement in relative change by MCID  70% (126) 60% (104) 1.16 (1.00, 1.36) 0.05 
Increase by LSC  26% (47) 39% (68) 0.66 (0.49, 0.90) 0.01 
Decrease by LSC  21% (38) 18% (31) 1.16 (0.76, 1.77) 0.48 
Suprapatellar pouch     
Improvement in absolute change by MCID  47% (53) 40% (45) 1.17 (0.86, 1.58) 0.31 
Improvement in relative change by MCID  67% (76) 53% (59) 1.27 (1.02, 1.57) 0.03 
Increase by LSC  26% (29) 39% (44) 0.64 (0.44, 0.93) 0.02 
Decrease by LSC  46% (25) 30% (19) 1.56 (1.09, 2.22) 0.02 
Other cavity     
Improvement in absolute change by MCID  41% (46) 32% (36) 1.27 (0.89, 1.80) 0.19 
Improvement in relative change by MCID  59% (67) 49% (54) 1.22 (0.95, 1.56) 0.11 
Increase by LSC  28% (32) 39% (44) 0.70 (0.49, 0.99) 0.04 
Decrease by LSC  44% (25) 34% (23) 0.41 (0.33, 0.50) 0.29 
All analyses compared baseline vs. 2-year outcomes  
*The results in this table were generated on an imputed dataset. 
Relative change = (absolute change/baseline value)/time interval. 
MCID, minimal clinically important difference was defined as the mean of the change among patients with functional improvement. 
LSC, least significant change criterion was used to correct measurement errors between multiple measures. CI, confidence interval. 
Bold p value indicates statistically significant difference at α=0.05. 
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8.4 Discussion 
This post-hoc analysis of the VIDEO study suggests that vitamin D supplementation 
retards the progression of effusion-synovitis over 24 months in vitamin D deficient knee OA 
patients. This is the first study using quantitative effusion-synovitis as an outcome measure in 
a clinical trial of OA. Most importantly, effusion-synovitis is able to regress or resolve 
suggesting its potential as a new approach for OA treatment. 
The initial report from the trial suggested that vitamin D supplementation over two 
years did not have a major effect on cartilage morphology and knee pain in OA patients with 
low serum vitamin D levels (240). Results from this secondary analysis suggest a beneficial 
effect of vitamin D supplementation on effusion-synovitis particularly in the suprapatellar 
region in knee OA patients with vitamin D deficiency. Not surprisingly, the effect was only 
evident in those with baseline effusion-synovitis. The effect size (1.9 ml) was small but 
statistically significant. The results were largely consistent when an improvement defined by 
MCID or an increase or decrease defined by LSC was used as an outcome, suggesting that 
effect of vitamin D supplementation on effusion-synovitis was not due to a measurement 
error and is large enough to be of clinical importance. The possible biological mechanism is 
that vitamin D could alter the inflammatory status by modulating pro-inflammatory mediators 
(239) through VDRs signalling pathways in the inflammatory OA phenotype.  
In our previous studies, we reported that effusion-synovitis, particularly in 
suprapatellar pouch, predicted worsening of knee pain, which was independent of other joint 
structural changes (169). In addition, it was significantly associated with cartilage defects and 
bone marrow lesions (94) over time. Effusion-synovitis in other regions was inconsistently 
associated with the progression of structural abnormalities, indicating effusion-synovitis in 
other regions was less clinical relevant possibly due to the limited joint space (94). Therefore, 
therapies targeting suprapatellar effusion-synovitis are most likely to have effect on disease 
progression and symptoms in knee OA. Effusion-synovitis volume in suprapatellar pouch 
responded well to vitamin D treatment in this trial. Its capacity to resolve over time indicates 
that it is sensitive to change. Our findings suggest that suprapatellar pouch effusion-synovitis 
can be used as an outcome measure in future clinical trials. 
There were several limitations to our study. First, as this is a post-hoc analysis it 
requires confirmation in further studies (241). Nonetheless, the results of the current study are 
biologically plausible. Further, the sample size in the original trial had sufficient power to 
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address the research question in the current study. Indeed, we were able to detect quite small 
changes in effusion-synovitis even if the sample size decreased by 50% after exclusion of 
those without baseline effusion-synovitis. Second, MRI coronal planes were used at one 
clinical site so regional effusion-synovitis was unable to be measured in all participants. This 
may reduce the power to detect significant effects of vitamin D supplementation on regional 
effusion-synovitis.  
In conclusion, vitamin D supplementation may retard progression of effusion-
synovitis in patients with knee OA and low 25-(OH)D levels. Effusion-synovitis volume is 
clinically relevant to OA so vitamin D treatment has potential to improve clinical outcomes 
of knee OA. Effusion-synovitis volume can be utilised as an outcome measure in future OA 
trials.  
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9.1 Summary 
OA is one of the most common joint disorder and the leading causing of pain and 
disability in adults. The social and economic burden associated with OA is increasing in the 
ageing population. Despite its large impact, there are no proven treatments, which stop or 
delay the progression of the disease. In Australia, OA affects over 1.9 million people costing 
the economy around $1.6 billion annually (1). OA manifests as alterations of the whole joint 
structure, including degradation of cartilage, subchondral bone, menisci and synovium. The 
diagnosis of OA is currently based on radiographic criteria (e.g., JSN, JSW) and clinical 
symptoms (e.g., pain and loss of function). However, the limitations of radiography (e.g., 
technical issues, precision and sensitivity) have led to research into alternative parameters for 
monitoring OA that could serve as biomarkers in drug development (242). It is now 
recognised that synovial changes occurring earlier in the disease process may precede 
structural damage which could be a potential disease indicator (89, 93). This thesis has 
described a series of prospective associations between synovial inflammation and disease 
progression and severity, and examined the effects of vitamin D supplementation on synovial 
inflammation in knee OA. It has presented novel and important findings which are 
summarised below. 
Chapter 4 describes the cross-sectional and longitudinal correlates between 
subregional effusion-synovitis and knee pain. Knee effusion-synovitis was measured on MRI 
at multiple sites, including suprapatellar pouch, central portion, posterior femoral recess and 
subpopliteal recess. Of these subregions, suprapatellar pouch effusion-synovitis, and posterior 
femoral recess effusion-synovitis, to a lesser extent, were found to be consistently associated 
with the prevalence and change in knee pain. These associations were found to be 
independent of cartilage defects and BMLs. In contrast, central portion and subpopliteal 
recess effusion-synovitis were not consistently associated with knee pain. Moreover, the 
associations of knee effusion-synovitis with non-weight-bearing was stronger than those with 
weight-bearing knee pain. 
Chapter 5 describes the cross-sectional and longitudinal correlations between 
subregional effusion-synovitis and knee structures. Knee structural features measured on X-
ray and MRI including osteophytes, JSN, cartilage defects, cartilage volume and BMLs were 
associated with effusion-synovitis. The longitudinal associations were observed mainly in the 
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suprapatellar pouch, to a lesser extent, the subpopliteal recess, but not in posterior femoral 
recess and central portion. The significant associations with cartilage defects were 
independent of BMLs, but the associations with cartilage volume, BMLs and radiographic 
changes were largely mediated by cartilage defects. Our results suggest that knee effusion-
synovitis, particularly in suprapatellar pouch, may be causally related to cartilage defects, 
which would lead to BMLs and cartilage loss over time. 
Chapter 6 investigated the natural history and clinical significance of effusion-
synovitis in community-dwelling older cohorts. The size of effusion-synovitis was 
quantitatively measured according to its maximal area on MRI. It was found that the 
proportions of worsening (29%) or improving (22%) effusion-synovitis were similar, with 
49% remaining stable. Baseline effusion-synovitis was associated with changes in cartilage 
measures and subchondral BMLs, but baseline cartilage measures and BMLs were not 
associated with a change in effusion-synovitis. This suggests a potential causal pathway from 
effusion-synovitis to cartilage and bone abnormalities, but not vice versa. Our findings 
confirmed that effusion-synovitis could be a precursor of OA, which was consistent with our 
previous findings that effusion-synovitis score assessed using semi-quantitative 
measurements was associated with increased incidence/progression of cartilage degradation 
and BMLs. Overall, these findings highlighted that effusion-synovitis is an attractive target 
for therapeutic intervention. 
Chapter 7 describes the dynamic changes of effusion-synovitis over 24 months and 
the relationship between effusion-synovitis and OA symptoms and structures in established 
knee OA patients. Quantitative volume measures and semi-quantitative scores of effusion-
synovitis were used. We found that baseline knee osteoarthritic outcomes, including 
osteophytes, JSN, cartilage defects, cartilage volume and BMLs were all significantly 
associated with changes in effusion-synovitis, but baseline effusion-synovitis was not 
associated with changes in osteoarthritic outcomes over 24 months. It is suggested that 
synovial inflammation is clinically relevant and can be the result of joint structural 
abnormalities in established knee OA. 
Chapter 8 examined the effects of vitamin D supplementation on effusion-synovitis in 
knee OA patients with low vitamin D levels. This post-hoc analysis of the VIDEO study 
showed that vitamin D supplementation reduced the progression of effusion-synovitis over 24 
months in vitamin D deficient knee OA patients. It is the first multi-centre RCT to examine 
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the effect of vitamin D on joint effusion-synovitis detected by MRI in patients with 
symptomatic OA. Given the fact that currently there are no disease-modifying drugs for OA, 
our study has provided direct evidence showing that monthly oral vitamin D supplementation 
is cost-effective and safe with a high compliance in controlling effusion-synovitis particularly 
in those with an inflammatory OA phenotype, which requires duplication by future studies. 
In conclusion, this series of related analyses of a prospective population-based study 
of community-dwelling older adults provide considerable insight into the role synovial 
inflammation plays in OA, suggesting that synovial inflammation is an attractive target for 
therapeutic intervention. Most importantly, a post-hoc analysis from a RCT in knee OA 
patients showed the beneficial effects of vitamin D supplementation in treating effusion-
synovitis. Recommendations for the future direction are provided in the following section. 
 
9.2 Future directions 
This thesis has presented several novel findings from a large prospective study of 
older community-dwelling adults and a RCT of vitamin D supplementation. It is suggested 
that effusion-synovitis plays a key role in the prediction of osteoarthritic outcomes and could 
serve as a therapeutic target. Knowledge of its role and relationships advance toward 
diagnostic criteria and clinical solutions related to knee OA. 
  
9.2.1 Synovial biomarker for diagnosis and treatment 
Imaging markers, from magnetic resonance and ultrasound, may be useful biomarkers 
in the evaluation of OA and in drug development in the field (102, 103, 202). From Chapter 4 
to Chapter 6, we established both qualitative and quantitative assessments for synovial 
inflammation termed as effusion-synovitis in multiple knee joint locations on MRI. It 
provides evidence for the inflammatory pathways in early OA. It suggested that effusion-
synovitis independently predicted worsening of knee pain after 2.6 years, regardless of other 
structural abnormalities. It also demonstrated a novel cascade that effusion-synovitis would 
cause cartilage defect development and/or progression, further leading to BMLs and diffuse 
cartilage loss over time. A promising trend is the use of MRI to monitor disease progression 
and onset by assessing those effusion-synovitis as well as other early structural changes (188, 
243, 244). However, the widespread use of MRI is limited by cost, availability and the 
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absence of a validated international atlas. In the future, the correlations between imaging data 
and clinical outcomes needs to be summarised by systematic literature reviews. A 
comparison of synovitis detected by MRI and other imaging techniques (e.g. 
ultrasonography) in terms of their relative sensitivity, specificity and prognostic value would 
also be required.   
Chapter 6 and Chapter 7 examined the natural history and clinical significance of 
effusion-synovitis, which found that effusion-synovitis was not static with similar proportions 
of both worsening and improving. Effusion-synovitis is expected to be an important disease 
endpoint in the future trial design. Chapter 8 showed that vitamin D was protective against 
progression of knee effusion-synovitis. This finding is novel but is from a post-hoc analysis 
from a RCT.  Future intervention trials are required with knee effusion-synovitis as the 
primary endpoint. Notably, the effusion-synovitis is variable and requires repeated 
assessments at multiple time points, which we were unable to do in our current study. Future 
studies are needed to determine which time interval is best to describe the variation of 
effusion-synovitis. 
Another attractive alternative is the soluble biochemical markers in blood, urine or 
synovial fluid samples, which could reflect dynamic and quantitative changes in synovial 
metabolism or inflammation, and, are therefore related to disease progression. In the setting 
of OA, a biochemical marker could be either an effector molecule (i.e., an operator of joint 
damage), the result of joint damage, or both, as in the case of cartilage extracellular matrix 
fragments, such an HA, that serve as both biomarkers and stimuli of the innate immune 
chronic wound healing response in the osteoarthritic joint (245). In our current study, we 
didn’t include systematic or localised soluble biomarkers that related to synovium. The 
relative impact of soluble biomarkers (e.g. cytokine, HA) produced by synovial tissue in OA 
pathogenesis needs to further study. Although there are disadvantages to sampling synovial 
fluid (e.g., discomfort to the patient; dislike of the procedure by practitioners; short half-life 
of some biomarkers) (246), in a research setting it can provide the most proximal quantitative 
data through biomarker analyses of the disease process and thereby can be invaluable for 
providing biological insights in the disease. 
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9.2.2 Inflammatory phenotype of OA 
OA can result from an extremely diverse range of pathologies, resulting in a 
heterogeneous mix of pathological processes and tissue subtypes amongst diagnosed patients. 
This creates a challenge for clinical trials that a treatment applied to a particular study group 
may only be effective in a small subset of that group. Therefore, identifying subtypes or 
phenotypes of OA is likely to assist in targeting treatment to patients who are the most likely 
to benefit (personalised medicine) (247). For example, when patients with low-grade 
inflammation were labelled as having an “inflammatory OA phenotype” (5), then synovitis 
may be a direct treatment biomarker that responses to anti-inflammatory interventions. 
Phenotypes postulated by other authors are post-traumatic (acute or repetitive), metabolic, 
ageing, genetic, symptomatic (248), and progressive/prognosis; each with different 
aetiological features, causal pathways, affected sites and effective treatments. One current 
major challenge is lack of universal criteria for phenotypes and characterisation for different 
stages of OA. To facilitate interpretation and comparability of biomarker studies across trials, 
study participants need to be described in detail with respect to symptoms, structure, function, 
and other known risk factors and medications. 
 
9.2.3 Challenges in treating synovial inflammation 
Although effusion-synovitis is proving to be an attractive target in OA, more clinical 
trials are needed to test if some relevant interventions are cost-effective for effusion-synovitis 
in knee OA. Many of the studies on the role of synovitis in OA cited in this thesis were 
recent, but several issues remain to be elucidated by future research. First, there is no 
standard in defining synovial inflammation as a study outcome. Numerous variations existed 
according to different assessment techniques, grading systems, populations and study designs 
and possibly the histological heterogeneity of synovial enhancement (e.g., effusion, 
hyperplasia, fibrosis, and inflammation) (249). In our study, it is possible that effusion-
synovitis resolution may occur with changes in some histological profiles but not others. The 
challenge is to identify which histological change will be responsive to therapy. More 
research is also needed to define the roles of the various cell types present in the synovial 
tissue. In addition, the role of synovial neovascularisation in the pathogenesis of OA was not 
fully understood. Finally, the influence of mechanical stress on synovial components remains 
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to be fully elucidated. While synovial inflammation is not a strictly specific feature of such a 
multifactorial joint disease, it is unlikely to constitute the primary endpoint for all OA 
phenotypes. However, it could be a valuable endpoint for inflammatory OA phenotype in 
future drug development. 
In conclusion, the analyses of data from a prospective cohort study and a RCT 
indicate that synovial inflammation plays a significant role in knee OA pathogenesis. This 
thesis supports a role for synovial changes in the early stages of the disease and its value of 
being a treatment target. Features of the synovial inflammation contribute to knee pain and 
predict important disease outcomes such as cartilage defect and BMLs. It can help identify 
subgroups and be used as an endpoint in future clinical trials. There remains a clear need for 
more research in the field. 
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